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 Mammalian cells possess a variety of different DNA repair pathways, which work 
together to safeguard genomic integrity upon encountering different types of DNA damage. 
Among all lesions, DNA double-strand breaks (DSBs) are most toxic and, if left unrepaired, 
results in loss of genetic information and genomic instability- a hallmark of tumorigenesis. Ataxia 
Telangiectasia Mutated (ATM) is a protein kinase, a master regulator of the DNA damage 
response, and is activated upon the formation of DSBs. ATM senses DNA DSBs through its 
accessory proteins and functions as a transducer of the DNA damage response (DDR), which 
entails the activation of genes involved in DNA repair, cell cycle checkpoint, and apoptosis. 
Consequently, loss of ATM results in increased genomic instability and compromised 
checkpoint regulation. Moreover, loss of ATM has been reported in various human cancers, and 
Atm-deficient mice uniformly develop thymic lymphomas, highlighting its role as a tumor 
suppressor.  
 Although ATM has been extensively studied, much of its known functions to date 
pertained to its kinase activity, and the structural function of ATM remains elusive. To 
investigate whether ATM possesses structural functions beyond its kinase activity, we 
generated a mouse model expressing kinase-dead (KD) ATM protein. Intriguingly, while Atm-/- 
are viable, AtmKD/KD and AtmKD/- mice were embryonic lethal and AtmKD/KD and AtmKD/- cells 
displayed greater genomic instability compared to ATM-null cells, suggesting that the presence 
of the ATM KD protein blocks additional DNA repair pathways that are not affected in ATM-null 
cells. In this context, we identified defects in homologous recombination, resolution of 
Camptothecin (CPT)-induced Topoisomerase-I lesions, and replication progression specifically 
 
 
in AtmKD/- cells beyond those observed in Atm-/-. Mouse model expressing KD ATM (AtmKD/-) in 
hematopoietic stem cells (HSCs) developed thymic lymphomas faster and more frequently than 
the corresponding model with the ATM-null HSCs, which was associated with increased 
genomic instability and loss of tumor-suppressor Pten. In collaboration with others, we showed 
that the majority of tumor-associated ATM mutations reported in TCGA are missense mutations 
and are highly enriched in the kinase domain, while Ataxia-Telangiectasia (A-T) associated 
germline ATM mutations are almost always truncating mutations leading to complete loss of 
ATM protein. This result suggests that ATM KD protein might be expressed in a significant 
fraction of human cancer. These results, for the first time, identified a previously unknown 
phosphorylation-dependent, structural function of ATM in the maintenance of genomic integrity 
and tumor suppression. Furthermore, the tumorigenicity and vulnerability to particular DNA 
damaging agents caused by the expression of the ATM KD protein relative to the loss of ATM 
highlight the importance of distinguishing the types of ATM mutations in tumors, and provide 
novel insights into the clinical use of specific ATM kinase inhibitors, as well as the prognosis and 
treatments of ATM-mutated cancers. 
 ATM has been reported to be frequently inactivated in human B-cell lymphomas, 
including up to 50% Mantle Cell Lymphoma (MCL), which represents around 6% of all Non-
Hodgkins Lymphomas (NHLs). MCL is characterized by the recurrent t(11;14)(q13;q32) 
translocation, which juxtaposes CCND1/BCL-1 to the IGH enhancer, leading to deregulated 
expression of CyclinD1 (CCND1). However, CyclinD1 overexpression in B cells alone is not 
sufficient to induce MCL in mouse models, and the role of ATM in the suppression of B-cell 
lymphomas is not well understood, in part due to the lack of ATM-deficient mature B-cell 
lymphoma models. To address this, we generated a mouse model that combines conditional 
deletion of ATM specifically in early progenitor B-cells via Mb1cre, and overexpressing CyclinD1 
in lymphoid cells via EµCyclinD1 transgene. While ATM loss alone resulted in the development 
 
 
of indolent, clonal, mature B-cell lymphoma, combined ATM-loss and CyclinD1 overexpression 
accelerated and increased the incidence of B-cell lymphoma. Furthermore, ATM-loss combined 
with CyclinD1 overexpression led to greater genomic instability and the expansion of naïve 
ATM-deficient B-cells in the spleen. This study, for the first time, developed an ATM-deficient B-
cell lymphoma model and demonstrated a synergistic function of ATM and CyclinD1 in pre-GC 
B-cell proliferation and lymphomagenesis. Furthermore, the mice described here provide a 
prototypic animal model to study the pathogenesis of human MCL, for which there are no 
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ATM: master regulator of the DNA damage response 
 
Ataxia Telangiectasia Mutated (ATM) was initially discovered as the gene mutated in 
Ataxia-Telangiectasia (A-T) syndrome- a rare, congenital neurodegenerative disorder 
characterized by motor neuron ataxia caused by cerebellar degeneration, and ocular 
telangiectasia – dilation of blood vessels in the eyes. A-T patients also display hypersensitivity 
to radiation, and heightened predisposition to leukemia and lymphoma (McKinnon 2012). ATM 
gene is located on human chromosome 11q22.3 (9qA5.3 in mice) and encodes a 3056 amino 
acid (3066 in mice), 370kDa, Serine/Threonine (Ser/Thr) protein kinase, which belongs to the 
PI3-Kinase-like-protein-kinase (PIKK) family that also includes DNA-dependent Protein Kinase 
catalytic subunit (DNA-PKcs), Ataxia Telangiectasia and Rad3-related (ATR), mammalian 
Target of Rapamycin (mTOR), and Suppressor of Mutagenesis in Genitalia 1 (SMG1), and 
Transformation/Transcription domain-associated Protein (TRRAP). TRRAP is a transcriptional 
co-activator and is the only PIKK that does not have kinase activities. PIKKs all possess long, α-
helical N-terminal HEAT repeats (Huntingtin, Elongation factor 3, protein phosphatase 2A, and 
Yeast target of rapamycin), followed by a FAT (conserved in FRAP, ATM, TRAAP), a PI3-
Kinase like catalytic domain and a FAT-C (FAT C-terminal) domain in the C-terminus. Although 
the crystal structure of ATM has yet to be solved, previous published structures of DNA-PKcs 
and mTOR, and data from cryo-electron microscopy (CryoEM) based structural rendering of 
ATM suggest that the protein is composed of an “head” and an “arm” domain, the latter of which 
undergoes major conformational changes upon interaction with DNA (Llorca, Rivera-Calzada et 
al. 2003, Sibanda, Chirgadze et al. 2010, Yang, Rudge et al. 2013) 
The best characterized function of ATM is its role as the master regulator of the DNA 
damage response (DDR) upon DNA double-strand breaks (DSBs). At physiological state, ATM 
normally exists as inactive homodimers predominantly in the nucleoplasm (Bakkenist and 






on Ser1981 (S1987 in mice) among others (e.g. Ser367, Ser1893 in humans) and its 
relocalization to the site of DSBs (Bakkenist and Kastan 2003, Kozlov, Graham et al. 2006). 
Although ATM auto-phosphorylation is widely accepted as a marker for ATM activation, the 
exact role of ATM auto-phosphorylation is still controversial. While mutant ATM with an alanine 
substitution at Ser1981 could not be fully activated in human cells and fail to form stable foci at 
DSB sites, transgenic mice expressing only the mutated ATM with alanine substitute at 
Ser1987, and two other auto-phosphorylation sites, display no measurable defects in ATM 
activation (Bakkenist and Kastan 2003, Pellegrini, Celeste et al. 2006, Daniel, Pellegrini et al. 
2008, So, Davis et al. 2009). ATM is also known to undergo other post-translational 
modifications (PTMs), including acetylation at Lys3016 by acetyltransferase TIP60 that is 
thought to be essential for its activation (Sun, Xu et al. 2007). Upon DSB formation, ATM is 
recruited to the DSBs by the MRE11-NBS1-RAD50 (MRN) complex, through direct interaction 
with the C-terminal tail of NBS1 (You, Chahwan et al. 2005). The MRN complex acts as a 
“sensor” of DNA DSBs, and is one of the first protein complexes to localize at the break site. 
Binding of MRN to the DNA allows the protein complex to undergo conformational changes that 
promotes the tethering of the coiled-coil and zinc-hook structure of RAD50 from opposing MRN 
 
Figure 1-1: The ATM Protein 
Schematic domain structure of ATM protein. Relative amino acid (A.A.) positions for the domains are 
shown below. Selected residues, including those that undergo post-translational modifications, are also 




complexes to bring together the two DNA ends (Hopfner, Craig et al. 2002, Moreno-Herrero, de 
Jager et al. 2005, Wiltzius, Hohl et al. 2005). Recruitment of ATM to DSB sites via MRN is 
critical for its function, as loss of function mutations in MRE11 or NBS1 cause A-T-like disorder 
(ATLD) and Nijmegen breakage syndrome (NBS1), respectively, that share clinical features with 
A-T syndrome. In addition to the MRN dependent activation of ATM induced by DSBs, ATM can 
also be activated independent of MRN by reactive oxygen species (ROS), which leads to the 
formation of disulfide linkage at Cys2991 between two ATM proteins to form dimers. It is thought 
that ROS-activated ATM could translocate to the cytoplasm and upregulate levels of NADPH in 
the mitochondria to relieve cellular oxidative stress (Guo, Deshpande et al. 2010, Guo, Kozlov 
et al. 2010).  
 ATM phosphorylates over 700 potential substrates (Shiloh and Ziv 2013) preferentially 
on Serine and Threonine residues followed by a Glutamine (S/TQ motifs). ATM substrates 
function in cell cycle arrest, DNA repair, chromatin condensation/relaxation and, when 
necessary, cell death. Most notably, ATM phosphorylates Histone H2A variant H2AX at Ser139. 
H2AX comprises ~2-20% of all H2A proteins in mammalian cells (Fernandez-Capetillo, Lee et 
al. 2004). Phosphorylated-H2AX (termed γH2AX) serves as a docking site for numerous effector 
proteins (e.g. MDC1, 53BP1) involved in DDR, further promoting the recruitment and retention 
of factors required for DSB repair at the break site. In addition, ATM phosphorylates and 
activates other kinases, most notably checkpoint kinases 1 and 2 (CHK1/2), which can then 
phosphorylate p53 at Ser20 to promote its dissociation from MDM2- E3 ubiquitin ligase, and 
stabilize p53 protein to elicit checkpoint activation and apoptosis. ATM can also directly 
phosphorylate Ser15 and Ser46 on p53, as well as Ser395 on MDM2 to relieve MDM2-mediated 
p53 degradation, leading to its stabilization (Saito, Goodarzi et al. 2002, Berger, Stahl et al. 
2005, Jenkins, Durell et al. 2012). ATM almost exclusively phosphorylates KRAB-associated 




(Ziv, Bielopolski et al. 2006). In the absence of ATM, γH2AX and CHK2 are phosphorylated 
through compensatory activities via ATR or DNA-PKcs (Brown and Baltimore 2003, Stiff, 
O'Driscoll et al. 2004). Accordingly, although mice deficient for either ATM or DNA-PKcs are 
viable, mice lacking both are embryonic lethal and display severe impairments in DDR, DNA 
repair and lymphocyte development (Gurley and Kemp 2001, Callen, Jankovic et al. 2009, 
Gapud, Dorsett et al. 2011, Zha, Jiang et al. 2011). 
 While the signaling function of ATM has been extensively studied, whether the large 
ATM protein possesses any structural functions beyond its kinase activity remains elusive. 
ATM-specific kinase inhibitors, including KU55933, CP466722, and KU60019 have been 
developed and widely used in many studies, (Hickson, Zhao et al. 2004, Rainey, Charlton et al. 
2008, Golding, Rosenberg et al. 2009). Treatment of wildtype cells with these kinase inhibitors 
largely phenocopies the complete loss of ATM, including diminished phosphorylation of ATM-
specific substrates, and radio- and chemo-sensitization of cells to DNA damaging agents 
(Hickson, Zhao et al. 2004, Rainey, Charlton et al. 2008, Golding, Rosenberg et al. 2009). 
However, several studies suggest that ATM kinase inhibition results in additional defects in DNA 
repair that were not observed in cells lacking ATM protein, indicating a possible structural 
function of ATM in DNA repair (White, Choi et al. 2010, Shiloh and Ziv 2013). This question will 
be investigated and discussed further in chapters 2-4. 
 
Mammalian DNA double-strand break repair pathways 
 
 DNA DSBs are highly genotoxic lesions which, if left unrepaired, can result in genomic 
instability, cell death, and tumorigenesis. Mammalian cells consistently suffer from DSBs as 
result of exposure to genotoxic agents, irradiation, metabolic and oxidative stress, and as  





Figure 1-2: ATM-mediated DNA damage response 
Upon DSB formation, ATM localizes to the site of DNA DSBs and activate a number of downstream 
targets involved in DNA repair, cell cycle checkpoint regulation, chromatin relaxation, and apoptosis. 
Adapted from (Shiloh and Ziv 2013) 
 
to be precisely and efficiently repaired to maintain genomic integrity. In mammalian cells, there 
are two major DNA DSB repair pathways: the Non-Homologous End-Joining (NHEJ) and the 




also contributes to the pathway choice by promoting end-resection, the first step of HR (Bakr, 
Oing et al. 2015). Classical NHEJ (C-NHEJ) is a non-templated, error prone pathway that 
entails direct joining of DSBs. C-NHEJ functions throughout all cell cycle phases and is the 
predominant repair pathway in the G1 phase of the cell cycle when the homologous template is 
not usually available. Ku70/80 (Ku86 in human) protein complex binds to the ends of the DSB, 
initiate C-NHEJ, and recruit DNA-PKcs and Artemis endonuclease, which together processes 
the DNA ends (e.g. hairpin opening), among other functions (Lieber, Ma et al. 2003). The 
formation of XLF/CERNUNNOS-XRCC4-LIG4 filaments on the DNA is thought to bridge the two 
participating DNA ends, where LIG4 catalyzes the ligation reaction to complete the joining 
process (Andres, Vergnes et al. 2012). In contrast to C-NHEJ, HR is a template-mediated, error-
free pathway of DSB repair. HR activity is largely restricted to S-phase and G2 phases of the 
cell cycle, when the sister-chromatid is available as a template (San Filippo, Sung et al. 2008). 
HR is initiated by 5’ to 3’ resection of the break site by the endo and exo-nucleases, including 
MRE11 with the help of CTIP (referred to as RBBP8 in the NCBI), and EXO1 (Symington and 
Gautier 2011). Resection of the ends results in the exposure of 3’ single-stranded DNA (ssDNA) 
overhangs that are coated by ssDNA binding protein RPA. RPA is hyper-phosphorylated by 
PIKKs, most notably at sites Ser4, Ser8, and Thr21 (Binz, Sheehan et al. 2004), which primes 
their removal from the ssDNA ends by RAD52 and BRCA1/2, and replacement by RAD51 
filaments (McIlwraith, Van Dyck et al. 2000). The coating of the ssDNA by Rad51 filaments 
primes the free DNA end for strand invasion- allowing the free DNA end to undergo homology 
search. In mitotic cells, the homologous template used for repair is primarily on the sister 
chromatid, while duing meiosis, homologous chromosomes are often the preferred template 
(Keeney 2001, San Filippo, Sung et al. 2008). The invasion and annealing of the donor DNA to 
its homologous sequence generates a Displacement loop (D-loop). The recapturing and 
reannealing of the invading strand to the original, non-template strand generate double Holliday 










Figure 1-3: Pathways of DNA double-strand break repair 
NHEJ and HR are the two major pathways of DNA repair in mammalian cells, with MMEJ/A-EJ 
constituting a third, minor pathway. Adapted from (Barlow and Rothstein 2010) 
 
such as MUS81 SLX1and GEN1 (Ip, Rass et al. 2008, Castor, Nair et al. 2013, Sarbajna and 
West 2014). Depending on the relative orientation of the cleavage at the two cross sites by the 
structure-specific endonuclease, HJ resolution can result in either a non-crossover event, where 
the chromosomal regions flanking the break sites are not exchanged, or a crossover where the 
resulting ends exchange sister chromatids. BLM helicase brings the two HJs in close proximity 
to allow Top3 to resolve it, which always results in non-crossover products (Wu and Hickson 
2003, Liberi, Maffioletti et al. 2005). In cases when the second strand is not recaptured and the 
double HJs do not form, the invading strand can be displaced from the D-loop and re-anneal to 
the original, non-invading strand in a process known as synthesis-displacement strand 
annealing (SDSA) which does not result in a crossover. Alternatively, cells can also undergo 
Break-Induced Replication (BIR), where the non-invading second end is lost, and the invading 
strand can continue to synthesize the new strand until  it reaches the end of the chromosome or 
is permanently displaced from the D-loop (Llorente, Smith et al. 2008). The recently emerged 
Microhomology-Mediated End Joining (MMEJ), also referred to as Alternative End-joining (A-
EJ), constitutes a third, less well-characterized DSB repair pathway. Although detailed 
mechanisms are still not well established, MMEJ relies on the presence of sequence 
microhomology flanking a DSB. These MH anneals to each when exposed upon resection, and 
effectively convert a DSB to two single strand breaks. As such, ligation during MMEJ is thought 
to be catalyzed by XRCC1/LIG3 and  will result in the loss of the intervening sequences 






DNA repair and lymphocyte development 
 
 Developing lymphocytes generate programmed DSBs during the assembly of antigen 
receptor gene via V(D)J recombination that joins the germline Variable (V), Diversity (D), and 
Joining (J) gene segments to form the functional B or T cell receptor (BCR [Immunoglobulin, Ig] 
or TCR). This process is initiated by lymphocyte-specific recombination activating genes 
(RAG)1 and 2, which recognize and bind recombine signal sequences (RSSs) - a set of 
conserved heptameric and nonameric sequences flanking either a 12bp or 23bp spacer 
sequence located immediately adjacent to each germline V, D or J segments. Efficient 
recombination only occurs between RSS with a 12bp spacer sequence to another with the 23bp 
spacer- termed the 12-23 rule (van Gent, Ramsden et al. 1996). RAG binding at the RSS results 
in the cleavage between RSS and the V/D/J segment that  generates four ends, two “signal 
ends” containing the cleaved RSSs, and two “coding” ends containing the DNA encoding V, D 
or J segments. The two signal ends are blunted and 5’ phosphorylated, and can be readily 
ligated together to form signal joint, while the two coding ends are hairpinned and cannot be 
directly ligated to form the coding joint. Coding ends are then processed by Artemis 
endonuclease, which opens the hairpin to allow ligation. If the V(D)J recombination occurs in the 
deletional orientation (the case of most Ig and TCR genes), the two signal ends join to form an 
excision circle containing the intervening sequence. Due to opening of the hairpin outside of the 
apex by Artemis, and the terminal deoxynucleotidyl transferase (TdT) activity at the coding 
ends, the coding joint is imprecise. This imprecision contributes to antigen receptor gene 
diversification and the generation of high-affinity antigen receptors. The ligation between the two 
signal and coding ends (to form the signal and coding joints, respectively) is exclusively 
mediated by the ubiquitously expressed C-NHEJ machinery. While not essential for the process, 
ATM plays critical roles in promoting efficient and precise DSB repair during V(D)J 




accumulation of unrepaired coding ends and mis-joining of one signal end with another coding 
end (to form hybrid joints) (Bredemeyer, Sharma et al. 2006). In addition, ATM plays a role in 
promoting end resection and also promotes efficient end-ligation- a function partially 
complemented by XLF/CERNUNNOS in the absence of ATM (Zha, Guo et al. 2011). However, 
ATM is dispensable for signal joint formation, as well as extrachromosomal V(D)J recombination 
in vitro (Hsieh, Arlett et al. 1993, Gapud, Dorsett et al. 2011). This selective function of ATM in 
coding, but not signaling join formation, maybe in part due to a role of ATM in promoting Artemis 
recruitment (Jiang, Crowe et al. 2015). Expression of antigen receptor gene products are 
essential for proper lymphocyte development, as both human patients and mice deficient in 
essential NHEJ genes exhibit severe-combined immunodeficiency (SCID) due to the lack of 
mature lymphocytes. Accordingly, the developmental blockage of lymphocytes in NHEJ-
deficient mice can be rescued by the introduction of transgenes expressing pre-rearranged 
antigen receptor gene products (Yan, Boboila et al. 2007). In this context, ATM deficiency 
impairs T cell development without significantly affecting naïve B cell development, despite the 
accumulation of IgH breaks in ATM-deficient immature B cells (Callen, Jankovic et al. 2007) 
 Human and mouse  encode four T-cell receptor (TCR) genes- TCRα, β, γ,δ,. TCR 
rearrangement begins in the thymus during the CD4-CD8- stage (double negative, DN) and lead 
to the generation of two functional T-cell subtypes: αβ T cells or γδ T-cells, based on the surface 
expression of TCRα/β or TCRγ/δ. In αβ T-cells, which comprises the majority of the T-cell 
population, successful V(D)J rearrangement of TCRβ is necessary for the transition from a DN3 
stage to the DN4 stage, then to CD4+CD8+ (double positive, DP)(Germain 2002). Expansion 
and proliferation of the cells in the late DN3 and DN4 stage create a large pool of T cells before 
the rearrangement of the TCRα locus. At the DP stage, cells undergo rearrangement at the 
TCRα locus, and successful expression of the TCRα allows the positive and negative selection 




positive (SP) cells. SP cells, or naïve T-cells, then exit the thymus and enter the periphery. Both 
ATM-deficient mice and A-T patients display slightly reduced peripheral lymphocyte number, in 
part due to a partial blockade of T-cell development at the DP to SP transition due to aberrant 
TCRα rearrangement (Borghesani, Alt et al. 2000, Schubert, Reichenbach et al. 2002). 
 Ig gene products are assembled in developing B-cells in the Bone Marrow. In 
B220+CD43+ Pro-B cells, immunoglobulin heavy chain locus (IgH) undergoes ordered V(D)J 
recombination with the joining of the  DH and JH segments  first, followed by joining of selected 
VH segments to DJH. The assembly of the IgH in Pro-B cells results in the expression of a pre-
BCR- composed of a rearranged IgH paired with a surrogate light chain, transition to 
B220+CD43-  Pre-B cells, and initiation of Ig light chains (IgL)- λ or κ (Igλ, Igκ) rearrangement. 
Successful rearrangement of IgL triggers the transition from Pre-B cells to IgM+B220+ naïve B-
cells, which can now migrate into the periphery. In secondary lymphoid organs, such as lymph 
nodes and the spleen, naïve B-cells undergo additional genomic rearrangement events in 
specialized structures known as Germinal Centers (GC). In GCs, B-cells undergo class switch 
recombination (CSR), and somatic hypermutation (SHM) in the light and dark zones, 
respectively. Activation-Induced Cytidine Deaminase (AID) initiate CSR by converting Cytidines 
(C) to Uracil (U) in the transcribed Switch (S) regions of IgH in slowly proliferating B-cells 
(Muramatsu, Kinoshita et al. 2000). The C to U transitions create base pair mismatches, which 
are recognized by the Mismatch Repair (MMR) and Base-Excision Repair (BER) pathways, 
including Uracil DNA Glycosylase (UNG) and Apurinic/apyrimidinic Endonuclease 
(APE)(Stavnezer, Guikema et al. 2008). This process requires the concomitant transcription of 
the S-regions. MMR/BER recognition and excision of the converted bases in transcribed S-
regions generate nicks which, if closely spaced, eventually lead to DSBs. Joining of the DSBs 
generated in the S-region preceding the default constant region Cµ (Sµ) with breaks in 




with same antigen specificity, but different effector functions. Although CSR-associated DSBs 
are mainly repaired via classical NHEJ, MMEJ could support as much as 25-50% of the CSR 
activity in the absence of classical NHEJ (Soulas-Sprauel, Le Guyader et al. 2007, Yan, Boboila 
et al. 2007, Han and Yu 2008, Boboila, Yan et al. 2010). In vitro analyses of ATM-deficient B-
cells showed reduced CSR efficiency upon cytokine stimulation, and accumulate AID-
dependent chromosomal translocations and breaks involving the IgH locus (Lumsden, McCarty 
et al. 2004, Reina-San-Martin, Chen et al. 2004, Franco, Alt et al. 2006). Accordingly A-T 
patients display reduced serum concentration of IgA, IgG2, and IgE, (Sanal, Ozaltin et al. 1998, 
Nowak-Wegrzyn, Crawford et al. 2004). SHM on the transcribed hypervariable region exons is 
also initiated by AID in the rapidly proliferating B-cells in the dark zone of the GC. The nicks that 
are generated during SHM mostly results in single nucleotide exchanges, although a small 
subset (~6%) of SHM-related lesions include DSBs which result in deletions and duplications 
(Bross, Fukita et al. 2000, Papavasiliou and Schatz 2000, Klein and Dalla-Favera 2008). 
Mutations created in the hypervariable region of the IgH and IgL further contribute to antibody 
diversification and the generation of higher affinity antibodies. 
 
ATM as a tumor suppressor in lymphocytes 
 
As lymphocytes undergo programmed DSBs that require efficient and timely repair, 
errors during V(D)J and CSR result in chromosomal translocations that are frequently observed 
in lymphoid malignancies. Recurrent translocations involving the antigen receptor loci and proto-
oncogenes are a hallmark of various types of human lymphomas. Additionally, in a p53-deficient 
background, mice deficient for all known NHEJ factors (except XLF), develop recurrent IgH- c-
Myc translocations and amplifications, and succumbed to pro-B cell lymphomas (Frank, 











































1% (Takeuchi, Koike et al. 1998) 
Table 1.1: List of lymphomas with frequent ATM mutations 
Five human lymphomas, and their common cytogenetic karyotype, with most frequently observed biallelic 
inactivation of ATM (ATM mutations). 
 
associated breaks in the IgH locus on chromosome 12 translocate to a region downstream of 
the c-Myc locus located on chromosome 15, generating a dicentric chromosome. The newly 
generated dicentric chromosome undergoes break-fusion-bridge (BFB) cycles that ultimately 
results in the amplification of c-Myc (Zhu, Mills et al. 2002, Gostissa, Yan et al. 2009).These 
observations highlight the importance of proper maintenance of genomic integrity by necessary 




ATM plays a critical role in promoting efficient V(D)J recombination and CSR to prevent 
chromosomal translocations and genomic instability in developing lymphocytes. Consequently, 
~25% of A-T patients develop B and T-lymphomas harboring recurrent translocations, and ATM 
is somatically mutated in various human lymphomas (Xu 1999, McKinnon 2012). Carriers for 
germline ATM mutations often develop mature T-cell Prolymphocytic Leukemia (T-PLL), 
characterized by t(14q11;14q32) or inv(14)(q11;32) translocations involving the TCR locus with 
the TCL1 oncogene (Pekarsky, Hallas et al. 2001). Somatic mutations of ATM have been 
identified in up to 50% of sporadic T-PLL and Mantle Cell Lymphoma (MCL), and 20% of CLL 
[Table 1.1] (Stilgenbauer, Schaffner et al. 1997, Gronbaek, Worm et al. 2002, Bea, Valdes-Mas 
et al. 2013). A large number of the cases contain gross chromosomal deletions around 11q22.3 
where ATM, as well as MLL2- another tumor suppressor gene in B-cells, are located, combined 
with the mutation on the other allele resulting in loss of heterozygosity (Gumy-Pause, Wacker et 
al. 2004, Cremona and Behrens 2014). In T-PLL, the majority of the mutations clustered in the 
region containing the PI3-Kinase domain of the protein (Stankovic, Taylor et al. 2001). In these 
lymphoid malignancies, deletion of ATM is believed to be an early event during the progression 
of lymphomagenesis due to the high prevalence of observed mutations in early stage of the 
disease (Jares, Colomer et al. 2007). The loss of ATM predisposes cells to aberrant 
rearrangements during development, which eventually leads to oncogenic translocations. 
Atm-/- mice recapitulate many phenotypes of A-T patients with homozygous germline loss 
of ATM. They display defects in T-cell development, hypersensitivity to irradiation, and develop 
early onset, aggressive thymic lymphomas in ~100 days (Barlow, Hirotsune et al. 1996, Xu, 
Ashley et al. 1996). ATM-deficient murine thymic lymphomas are typically CD4+CD8+ or CD4-
CD8+, CD3lo, sTCRβ-, which share surface markers with human T-ALL. They also harbor 
recurrent t(12:14) chromosomal translocations that results in the amplification of a ~500kb 




of the thymic lymphomas carry deletions in regions surrounding Pten. Notch1 mutations and 
amplification occur in ~40% of the cases, recapitulating several frequent genetic lesions in 
human T-ALL (Zha, Bassing et al. 2010). Atm+/- heterozygous mice rarely develop lymphoid 
malignancies, consistent with the loss of heterozygosity observed in human patients and the 
need to loss both copy of ATM to abolish its tumor suppression function (Spring, Ahangari et al. 
2002).  
  Over 400 unique ATM mutations have been identified in A-T patients or cancers. While 
an overwhelming majority (~89%) of the A-T mutations are truncation mutations that abrogate 
protein expression, a significant fraction of cancer associated ATM mutations are missense 
mutations that have been confirmed, or predicted to retain significant ATM expression. 
However, little is known about the functional significance of these missense mutations. In 
addition, ATM-specific kinase inhibitors have been proposed to be used for both a chemo- and 
radio-sensitizing agent for the treatment various cancers. However, whether the presence of a 
kinase-inactivated ATM upon treatment of the cells with kinase inhibitor poses a risk remains 
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Background and Significance 
 
Recent study on ATM function has greatly benefited from the development of specific 
inhibitor for ATM kinase activity (Hickson, Zhao et al. 2004). While in most studies ATM kinase 
inhibitor reproduce the effect of ATM protein deficiency, several recent studies report additional 
defects in replication related DNA repair in ATM kinase inhibitor treated cells, but not in ATM 
null cells, suggesting potential kinase independent function of ATM protein (White, Choi et al. 
2010, Gamper, Choi et al. 2012). While the overwhelming majority of germline A-T patients 
carry truncation mutations that lead to the complete loss of protein, many somatic mutations in 
human lymphomas have been identified to be missense mutations. Some mutations identified 
have been confirmed to have the expression of the ATM protein with abrogated activity. 
However, the full functional consequence expressing a defective protein is not well understood.  
In this chapter, we report the generation and characterization of mouse model with 
D2880A/N2885K (corresponding to D2870A/N2875K in human) that leads to the expression of a 
kinase dead ATM (ATM KD) (Canman, Lim et al. 1998). Intriguingly, mice carrying AtmKD in 
homozygosity died during early embryonic development, despite normal embryonic 
development of Atm null mice (Atm-/-). We further show that Atm-/KD embryonic stem (ES) cells 
have proliferation defects and spontaneous genomic instability relative to Atm-/- ES cells. While 
the spontaneous genomic instability in Atm-/- ES cells are predominantly chromosomal breaks, 
consistent with the role of ATM in non-homologous end joining (NHEJ), Atm-/KD ES cells carry 
high levels of both chromatid and chromosomal breaks, indicating enzymatically- inactive ATM 
protein causes additional repair defects in post-replicative cell cycle phases. Despite increased 
genomic instability, Atm-/KD lymphocytes did not have defects in chromosomal V(D)J 
recombination and mature B cell immunoglobulin class switch recombination beyond those 
observed with Atm-/- alone. Together this study, for the first time, reveals an inhibitory function of 









AtmKD/KD, but not Atm+/KD mice, die during early embryonic development. 
 To generate mice expressing a kinase-dead ATM protein we introduced the previously 
described D2880A/N2885K (corresponding to D2870A/N2875K in humans) (Canman, Lim et al. 
1998, Bakkenist and Kastan 2003) double mutation in the sequence encoding the conserved 
catalytic loop [Fig. 2-1A] of the murine Atm gene along with a floxed Neomycin Resistant 
(NeoR) cassette (referred to as ATM KDN for the presence of NeoR cassette) [Fig. 2-1B]. We 
selected the D2870A/N2875K double mutation, since it was fully characterized for normal 
protein expression and the absence of kinase activity (Canman, Lim et al. 1998, Bakkenist and 
Kastan 2003). Six targeted clones were identified by Southern blot analyses [Fig. 2-1C] and the 
mutations were verified in 4 clones by genomic sequencing. Two independent targeted clones 
were injected for germ line transmission. Atm+/KDN chimeras were then bred with sperm specific 
Protamine-Cre transgenic mice (O'Gorman, Dagenais et al. 1997) to induce recombination 
between the loxP sites flanking the NeoR to generate the Atm+/KD mice, in which the kinase-
dead “AtmKD” allele is transcribed and expressed from the endogenous Atm promoter. Atm+/KD 
mice are normal in size, fertile, and have no detectable defects in lymphocyte development 
[Table 2.1, Fig. 2-5].  However no AtmKD/KD mice were identified in more than 100 pups 
generated by breedings between Atm+/KD mice (p-value for Χ2 test =4.0x10-8) [Table 2.1], 
indicating embryonic lethality.  This was unexpected since Atm-/- mice are viable and born at 
roughly Mendelian ratio. Timed heterozygous crosses further revealed that no live AtmKD/KD 
embryos could be found [Table 2.1] (p-value for Chi-Squared test=0.0056) even at embryonic 





Figure 2-1: Generation of Atm
KD
 allele 
A.) The corresponding sequence of the catalytic loop of human and mouse ATM kinase are aligned and 
the mutated residues are underlined. B.) The schematic diagram represents the murine Atm locus (top), 
targeting vector (2nd row), targeted allele (Atm
 KDN
, 3rd row), and the neo-deleted mutant allele (Atm
 KD
, 
bottom). The 5’ probe is marked as a black line. The exons and loxP sites are shown as solid boxes and 
open triangle respectively. The exon containing the KD mutation is marked as an open box. Restriction 
site designation: X=XhoI, RV=EcoRV, H=HindIII.  The map is not drawn to scale.  C.) Southern Blot 






                                                                                                                                                                                                                         








Table 2.1: Kinase inactive ATM leads to early embryonic lethality 
Genotype of embryos and live pups obtained from timed breeding between ATM
+/KD
 parents comparing to 
the expected Mendelian frequency, the chi-squared test p-value = 0.03 for E9.5-E10.5 embryos and 
=4.22x10
-6
 for live birth. N/A- Not Available. 
 
Total ATM+/+ ATM+/KD ATMKD/KD Absorbed Total Χ2 
E9.5-10.5 2 11 0 3 16 0.03 
Live Birth 27 45 0 N/A 72 4.2x10-6 
lethality of kinase-dead ATM protein is not caused by a classical dominant-negative mechanism 
since Atm+/KD mice and cells that express both ATM-WT and ATM-KD protein have no 
discernable phenotype.   
 
AtmKD/- embryonic stem (ES) cells have greater genomic instability than Atm-/- cells.  
To explore the causes of developmental failure in AtmKD/KD mice, we generated AtmKD/- 
ES cells and control Atm+/+and Atm-/- cells. To circumvent the embryonic lethality, we first 
derived AtmKDN/C ES cells. The previously characterized ATM conditional allele (AtmC) behaves 
as the WT allele and can be efficiently converted to a null (Atm-) allele upon Cre-mediated 
recombination (Zha, Sekiguchi et al. 2008, Zha, Jiang et al. 2011). We obtained six-independent 
AtmKDN/C clones and three control Atm+/C clones. AtmKD/- ES cells were then generated by 
infecting AtmKDN/C cells with Adenovirus expressing Cre-recombinase. While all 24 Cre-
transduced Atm+/C clones were genotyped as Atm+/-, indicating efficient recombination, only two 
of the 96 Cre-transduced AtmKDN/C clones were genotyped as AtmKD/-, implying that AtmKD/- cells 
have growth and/or survival defects. Western blot analysis verified that ATM-KD protein is 





Figure 2-2: Proliferation defects and increased genomic instability in Atm
KD/-
 embryonic stem cells 









 ES cells. B.) Fold increase of cell number relative to day 0, as 




 ES cells under normal growth 
conditions. Three independent experiments were performed in two independently derived Atm
 KD/-
 ES 
cells lines. The figure and the error bar represent standard deviation derived from quadruplicated cultures 
in one representative experiment. C.) Representative metaphases with genomic instability from Atm
 KD/- 
ES cells. Yellow arrows- Chromosome breaks, Red arrows- Chromatid breaks. D.) The frequency of 




 ES cells. 




 ES cells is 
0.002 and for chromosome breaks is 0.101. 
 
However, two independently derived AtmKD/- ES cell lines grew significantly slower than both 
Atm-/- ES and Atm+/+ ES cells, which grew at comparable rates [Fig. 2-2B] 
  We proceeded to measure spontaneous genomic instability in Atm+/+, Atm KD/- and Atm -/- 
ES cells using Telomere-FISH (T-FISH) assays (Franco, Gostissa et al. 2006, Zha, Sekiguchi et 




spontaneous cytogenetic abnormalities, while only18% of those derived from Atm -/- cells, and 
<2% of those derived from WT cells showed such abnormalities [Fig. 2-2C, D] In contrast to the 
predominant chromosome breaks in Atm -/- ES cells (Franco, Gostissa et al. 2006, Zha, 
Sekiguchi et al. 2008) [Fig. 2-2D] the cytogenetic aberrations in AtmKD/- ES cells were evenly 
distributed between chromosome (break involving both sister-chromatids) and chromatid 
(breaks involving one of the two sister-chromatids) breaks, with the most dramatic increase 
observed in chromatid breaks [Fig. 2-2C, D]. While chromosome breaks are derived primarily 
from DSBs that arise during the G1 phase of cell cycle, chromatid breaks often result from 
DSBs in S and G2 phases of the cell cycle, when HR is most active. Together, these results 
suggest that the physical presence of ATM-KD inhibits DNA repair, likely HR, in a manner that 
does not occur in the absence of ATM protein. Previous studies have identified both replication-
related DNA repair defects and increased chromatid breaks in cells treated with selective ATM 
kinase inhibitors (White, Choi et al. 2010, Gamper, Choi et al. 2012) but not in ATM null cells. 
While it is unclear if the effects of ATM kinase inhibitors on DNA repair are the same as those 
observed in AtmKD/- cells, our findings emphasize the need to distinguish the effects of ATM 
deletion and kinase inhibition in future studies.  
 
The effect of ATM-KD protein on lymphocyte development. 
To test the consequences of ATM-KD protein expression in somatic cells, we generated 
Rosa+/ER-CreAtmC/KDN mice. The ROSA26-ERCre (Rosa+/ER-Cre) allele ubiquitously expresses a 
Tamoxifen-inducible fusion protein of estrogen-receptor ligand-binding domain and Cre 
recombinase (ER-Cre) under the endogenous Rosa26 promoter (de Luca, Kowalski et al. 2005, 
Guo, McMinn et al. 2007). Lymphocyte development was then analyzed in conditional ATM KD 
(Rosa+/ER- CreAtmC/KDN) , conditional ATM null (Rosa+/ER- CreAtmC/C(-) ) and control (Rosa +/ER-




recombination of the AtmC and AtmKDN alleles was readily observed in bone marrow, thymus 
and spleen. Western blot of total thymocytes showed that ATM KD protein is expressed at 
levels similar to WT protein in thymocytes [Fig. 2-3A]. Upon irradiation, the levels of 
phosphorylated KAP-1 and H2AX (γ-H2AX) in thymocytes purified from Tamoxifen-treated 
Rosa+/ER-CreAtmC/KDN mice were comparable to those from Rosa+/ER-CreAtmC/C mice, confirming 
the loss of ATM kinase activity in AtmKD/- thymocytes [Fig. 2-3B]. Compared to WT controls 
(182±27x106), the total thymocyte number in Tamoxifen-treated Rosa+/ER-CreAtmC/KDN mice 
(60±17x106) was reduced to a level similar to  Rosa+/ER-CreAtmC/C (54±12x106) and Atm-/- 
(42±16x106) mice (n>=3 for each group). FACS analyses of Tamoxifen-treated Rosa+/ER-
CreAtmC/KDN mice revealed thymocyte-developmental defects, namely decreased TCRβ surface 
expression and decreased SP percentage in the thymus, comparable to those of Tamoxifen-
treated Rosa+/ER-CreAtmC/C or Atm-/- mice (Borghesani, Alt et al. 2000) [Fig. 2-4A]. Together these 
data suggest that kinase-dead ATM protein partially blocks T cell development and, by 
extension, chromosomal V(D)J recombination, to a level comparable to the absence of ATM 
protein. 
Similarly, B cell development in Tamoxifen-treated Rosa+/ER-CreAtmC/KDN mice was largely 
comparable to that of Atm -/- mice [Fig. 2-4A]. To test the effect of ATM-KD protein in CSR, we 
incubated partially purified (CD43-) Atm KD/- and control splenic B cells with anti-CD40 plus 
interleukin 4 (IL-4) for 4 days to stimulate CSR to IgG1. B-cells from Tamoxifen treated Rosa+/ER-
CreAtmC/C(-) mice performed CSR at ~40% of WT levels with increased genomic instability, similar 
to those of germline Atm-/- mice [Fig. 2-4A, B], confirming functional loss of ATM protein in B 
cells from Tamoxifen-treated Rosa+/ER-CreAtmC/C(-) mice.  Nevertheless, B cells from Tamoxifen 
treated Rosa+/ER-CreAtmC/KDN mice underwent CSR at levels comparable to their ATM-null 
counterparts [Fig. 2-4A, B]. Consistent with our findings on AtmKD/- ES cells, activated B cells 
from Tamoxifen-treated Rosa+/ER-CreAtmC/KDN mice accumulated greater genomic instability, 





Figure 2-3: ATM KD
 
lymphocytes are catalytically inactive 









 mice and control Atm
-/-
 mice. B.) Western blot for phosphorylated H2AX, phosphorylated KAP-1 
and total KAP-1and Actin in irradiated thymocyte (5 Gy) with or without pre-incubation with 15 µM ATM 
kinase inhibitor (KU55955, Tocris Bioscience) or 5µM DNA-PKcs kinase inhibitor (NU7441, Tocris 
Bioscience). Cell lysates were collected 2 hours after irradiation. ATMi- ATM inhibitor (KU55933, 
pretreated 1 hour at 15µM), DNA-PKi- DNA-PK inhibitor (NU7441, pretreated 1 hour at 5µM) 
 
results support the conclusion that the ATM-KD protein inhibits DNA repair in S and G2 phase 
of cell cycles. 
Transgenic expression of an autophosphorylation-mimetic, kinase-dead double mutant 
ATM rescues the embryonic lethality of ATM KD mice 
 ATM undergoes trans-autophosphorylation on Ser1981 (Ser1987), among other 
residues, upon activation. However, the exact function of ATM autophosphorylation is 
controversial. While human ATM with an alanine substitution at Ser1981 abrogated ATM 
activation and loss of retention at DNA damage sites, murine ATM with S1987A mutation, as 














Figure 2-4: Analysis of ATM KD lymphocytes 
A.) Representative flow cytometric analyses of total thymocytes stained with CD4, CD8, and TCRβ, and 
total splenocytes stained with B220 and IgM surface markers. For the B220/IgG1 marker staining, CD43- 
splenocytes were isolated and stimulated in culture with anti-CD40 and IL-4 for 4 days before staining. A 
total of five independent experiments were performed and one set of representative FACS analyses is 
shown. B.) Relative frequency of the IgG1
+
 cells among all B220
+





B cells. The data represents the average and standard deviation from 
at least five experiments. The chi-squared test p-values are marked in the graph. C.) The frequency (per 
metaphase) of chromatid and chromosome breaks measured by T-FISH analyses in stimulated B cells 
from WT, Atm
-/-








mice. The chi-squared 




 B cells cells is 0.007 and 
for chromosome breaks is 0.816. 
 
 
Figure 2-5: Characterization of Atm
+/KD
 mice 
Representative flow cytometric charts of total thymocytes stained with CD4, CD8, and TCRβ, bone 
marrow with B220, and CD43, and total splenocytes with CD4, CD8, B220, and IgM. A total of four 
independent experiments were performed and one set of representative FACS analyses is shown. 
 
mouse models (Bakkenist and Kastan 2003, Pellegrini, Celeste et al. 2006, Daniel, Pellegrini et 
al. 2008, So, Davis et al. 2009). The kinase-dead ATM does not display a classical dominant- 
negative phenotype, as Atm+/KD mice develop normally and do not display lymphocyte 
developmental defects as those observed in Atm-/KD mice [Fig. 2-5]. We hypothesized that trans-
autophosphorylation of the KD protein by the wildtype protein relieves the toxic effect of the KD. 





Figure 2-6: Generation of the autophosphorylation-mimetic, kinase-dead (DKD trangene) Atm 
Mouse. 
A.) General scheme for the generation of DKD Atm-/- mice. B.) FISH for the endogenous Atm locus and 
the DKD transgene using the ATM-containing BAC (RP24-122F10) as a probe on metaphases collected 
from ear fibroblasts from founder mice A and C. Yellow triangles indicate BAC integration sites. 
 
S1987D mutation and the KD mutation (referred to as DKD). The genomic sequencing encoding 
the S1987 and D2880/N2885 sites are ~23 kbs away from each other, rending it technically 
difficult to generate simultaneous mutations on the same allele with sequential targeting or 
breeding using the conventional targeting approach. We thus employed bacterial artificial 
chromosome (BAC) recombineering to introduce the two mutations into an Atm-containing BAC 
(RP24-122F10), and generated BAC transgenic (Tg) mice carrying the DKD allele.(Yang and 
Sharan 2003, Pellegrini, Celeste et al. 2006) [Fig. 2-6A]. Another group has utilized similar 
method to introduce two different ATM KD alleles (e.g. D2899A and Q2740P) and test their 





  Tg- DKD Tg+   













A Actual 12 16 9 6 15 10 68 0.74 
Expected 8.5 17 8.5 8.5 17 8.5   
C Actual 5 13 6 9 13 7 53 0.93 
Expected 6.625 13.25 6.625 6.625 13.25 6.625   
D Actual 11 22 7 3 7 7 57 0.03 
Expected 7.125 14.25 7.125 7.125 14.25 7.125   
E Actual 3 5 1 2 4 1 16 0.88 
Expected 2 4 2 2 4 2   
F Actual 4 4 2 3 5 0 18 0.55 
Expected 2.25 4.5 2.25 2.25 4.5 2.25   
Table 2.2: Tabulation of live-born mice between DKD Atm
+/-




also died during embryonic development (Daniel, Pellegrini et al. 2012). Each founder line 
positive for the DKD Tg were assessed for BAC integration using FISH, and backcrossed to 
Atm+/- to generate DKD Atm-/- mice [Fig. 2-6B]. 4 of the 5 transgenic lines that gave germline 
transmission of DKD produced viable DKD Atm-/- F2 offspring, rescuing the embryonic lethality 
of the KD [Table 2.2]. The rescue of the KD embryonic lethality could be due to the loss of 
transgene expression, which would render DKD Atm-/- mice to be the same as Atm-/-. RT-PCR, 
followed by KasI digestion to specifically detect DKD expression, confirmed the presence of 
DKD mRNA expression in ear fibroblasts harvested from DKD Atm-/- mice [Fig. 2-7A, B]. 
However, detectable level of ATM protein cannot be found by Western blot [Fig. 2-7C]. 
Additionally, DKD Atm-/- mice succumbed to thymic lymphomas similar to those observed in Atm-
/- mice [Fig. 2-7D]. Based on these finding, we consider the possibility that the S1987D auto-
phosphorylation-mimetic mutation on the KD protein causes the destabilization of the DKD 
protein, and rescues the embryonic lethality of just the KD alone. Consequently, DKD Atm-/- 






Figure 2-7: DKD Atm
-/-
 mice do not express ATM protein, and develop thymic lymphomas 
A.) RT-PCR scheme for both the wildtype and transgene-introduced DKD Atm allele. The DKD transgene 
contains an added KasI site that allows for distinguishing between the wildtype and DKD alleles. 
Expected PCR, digestion size fragments are indicated in bps. B.) RT-PCR of total RNA collected from ear 
fibroblasts harvested from F2 progeny of the indicated genotypes. C.) Western blot of ATM and Actin as a 







 Past studies of ATM function in DNA repair have focused primarily on its kinase activity. 
Here we and others, have shown that kinase-dead ATM proteins causes early embryonic 
lethality despite the normal embryonic development in the complete absence of ATM protein 




higher levels of chromosome instability, particularly chromatid breaks, relative to ATM-null cells. 
Despite the increased genomic instability, Atm KD/- lymphocytes carried out V(D)J recombination 
and CSR at levels comparable to ATM-null cells. Together these data suggest that while loss of 
ATM kinase activity and ATM-mediated phosphorylation of downstream targets compromise 
both NHEJ and, to a lesser extent, HR function, the ATM-KD protein elicits additional inhibitory 
effects in post-replication DNA repair, potentially HR. By uncovering unexpected functions for 
ATM protein in DNA repair and embryonic development, our study raises clinically relevant 
questions about the mechanism of ATM activation and the application of ATM kinase inhibitors. 
While NHEJ plays critical roles in lymphocyte-specific DSB repair events, it is largely 
dispensable for embryonic development (Lieber 2010). In contrast, most HR factors are required 
for embryonic development. In this context the embryonic lethality of AtmKD/KD, but not Atm-/- 
mice may reflect an inhibitory function of ATM-KD protein in a subset of HR. Consistent with this 
hypothesis, the most dramatic increase of general genomic instability in AtmKD/- cells over ATM 
null cells is chromatid breaks, which are typically associated with defects in S and G2 phase 
DNA repair. 
ATM belongs to the family of PI3K-related kinase (PIKK), which also includes DNA-PKcs 
and ATR. While ATR is activated by RPA-coated ssDNA (Shiotani and Zou 2009, Liu, Shiotani 
et al. 2011), ATM and DNA-PKcs are both activated by DNA DSBs, phosphorylate an 
overlapping pool of substrates (e.g., H2AX, KAP1, and p53) (Callen, Jankovic et al. 2009, Zha, 
Guo et al. 2011, Zha, Jiang et al. 2011) and have redundant functions during embryonic 
development and DNA repair (Gurley and Kemp 2001, Sekiguchi, Ferguson et al. 2001, Callen, 
Jankovic et al. 2009, Gapud, Dorsett et al. 2011, Zha, Jiang et al. 2011). It is possible that the 
presence of an enzymatically-inactive ATM protein might prevent DNA-PKcs, and potentially 
other PIKKs, from phosphorylating shared substrates, thereby disrupting DNA repair to a 




defects more severe than loss of either kinase alone (Callen, Jankovic et al. 2009), but AtmKD/- 
and Atm-/- B cells performed CSR at similar levels [Fig. 2-4A, B] inconsistent with inhibition of 
DNA-PKcs function in Atm KD/- B cells. Moreover, H2AX and KAP-1, two shared substrates of 
ATM and DNA-PKcs, are phosphorylated at comparable levels in AtmKD/- and Atm-/- B and T 
cells [Fig. 2-3D].  While phosphorylation of particular substrates of DNA-PKcs or DNA-PKcs 
itself may be inhibited in AtmKD/- cells, but not ATM-/- cells, our findings are inconsistent with 
global inhibition of DNA-PKcs activity in AtmKD/- cells. In this context, loss of ATM 
phosphorylation sites on DNA-PKcs leads to more severe defects in DNA repair than DNA-PK 
null mice (Zhang, Yajima et al. 2011). In addition, ATM carrying both the phosphomimetic at 
Ser1987 and kinase-dead mutations lead to its destabilization and lack of protein expression. 
The autophosphorylation of ATM may be a mechanism to prime the degradation of the protein 
after the DNA damage. As a consequence, mice heterozygous for the KD allele over wildtype 
have no discernable phenotype, consistent with the autophosphorylation-mediated degradation 
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Background and Significance 
 
In the previous chapter, we discovered that while Atm-/- mice are viable, mice solely 
expressing ATM KD are embryonic lethal. In addition, we observed greater genomic instability in 
both ES cells and lymphocytes expressing ATM-KD, we hypothesized that the ATM KD protein 
is blocking DNA repair through a mechanism not observed in Atm null cells. In particular, the 
greater accumulation of chromatid breaks in the telomere FISH assay, and early embryonic 
lethality suggest additional defects in the HR pathway. 
 In this chapter, we further investigate the pathways of DNA repair affected by the 
expression of ATM KD. We discovered that ATM KD ES cells display defects in HR, and AtmKD/- 
Mouse Embryonic Fibroblasts (MEFs) are more sensitive to Camptothecin (CPT) than Atm-/- 
(ATM-null) counterparts. Specifically, AtmKD/- cells were unable to upregulate γH2AX, Rad51 foci 
and subsequent sister-chromatid exchange upon CPT challenge, suggesting a defect elicited by 
the ATM KD protein upstream of DSB formation upon TopI-DNA adduct formation. Accordingly, 
AtmKD/- cells accumulated greater levels of DNA-bound Topoisomerase-I (TopI) covalent 
complexes (Top1ccs) upon CPT treatment compared to Atm-/- cells, indicative of a defect in the 
resolution TopI-DNA lesions generated by CPT treatment. The loss of DSB formation by ATM 
KD expression occurs via the blockage of structure-specific nucleases, such as SLX4 and 
MUS81, in a MRE11-dependent manner. AtmKD/- cells also displayed slower progression of 
replication, underlying defects in DNA replication resulting from ATM KD expression. We have 
thus identified novel structure-kinase roles of ATM in homologous recombination, removal of 









ATM KD cells are hypersensitive to Camptothecin (CPT), and cannot upregulate CPT-
induced Sister Chromatid Exchange (SCE) and RAD51 foci 
 To understand how expression of kinase-dead ATM increases genomic instability, we 
compared the genotoxin sensitivity of immortalized Rosa+/CreERT2Atm+/C, Rosa+/CreERT2AtmC/- and 
Rosa+/CreERT2AtmC/KD murine embryonic fibroblasts (MEFs). These cells were treated with three 
rounds of 4-OHT (200nM) to induce nuclear translocation of ER-fused Cre recombinase, 
inactivation of the conditional AtmC allele, and generation of Atm+/-, Atm-/- and AtmKD/- MEFs, 
respectively [Fig. 3-1A] (Yamamoto, Wang et al. 2012). All experiments were conducted on 
freshly deleted cells to avoid secondary alterations in genetically-unstable Atm-deficient cells. 
While both AtmKD/- and Atm-/- MEFs were similarly sensitive to ionizing radiation (IR), AtmKD/- 
cells were especially sensitive, relative to Atm-/- and Atm+/- cells, to the Topoisomerase I inhibitor 
camptothecin (CPT) [Fig. 3-2B]. The specific CPT hypersensitivity of AtmKD/- cells does not 
appear to reflect an inability to process blocked DNA ends in general, as both Atm-/- and AtmKD/- 
cells were equally sensitive to the topoisomerase II inhibitor etoposide [Fig. 3-2C].  Replication 
defects in general is also unlikely to account for the CPT hypersensitivity, since AtmKD/- cells are 
not especially sensitive to hydroxyurea (HU) or aphidicolin (APH), two agents that block 
replication [Fig.3-2D, 3-2E]. These findings indicate that expression of kinase-dead ATM protein 
specifically sensitizes cells to Topo-I poisons, and suggest that Topo-I inhibitors might be 
prioritized for the treatment of cancers with catalytically-inactive ATM mutations.  
CPT and related clinical Topo I blockers (Irinotecan or Topotecan) trap Topo I in a 
covalent complex (“Top1cc”) at the 3’ end of the single-strand DNA nick induced by Topo I 





Figure 3-1: Analyses of immortalized Atm
KD/-
 and control MEFs 
A) Treatment scheme of immortalized Rosa-CreERT2 MEFs. B.) PCR and C.) Western blot analyses of 
the MEFs before and after three rounds of 4OHT treatment (200nM). The result confirmed the efficient 
ATM deletion and the expression of kinase-dead ATM protein. The Western blot also shows the normal 




interferes with transcription and replication, and ultimately elicits cellular cytotoxicity (Pommier 
2006). In this regard, we showed that AtmKD/- MEFs accumulated Top1cc even at a very low 
dose of CPT (0.1µM) [Fig. 3-3D]. At high concentrations (15µM CPT), Atm-/- cells also 
accumulates Top1cc at a higher level than Atm+/+ cells [Fig. 3-3D], likely due to a kinase- 
independent function of ATM previously described in neuronal cells (Alagoz, Chiang et al. 2013, 
Katyal, Lee et al. 2014). The antibody used for Top1cc assay was developed against a peptide 
that lies within 10 amino acids of the tyrosine covalently linked to DNA (Bethyl, Cat: A302-590). 
Therefore, the Top1cc that accumulate in AtmKD/- cells may be comprised of intact Topo I or, 
more likely, a Topo I proteolytic fragment (Pommier 2006). In this context, CPT-induced 
degradation of intact Topo1 protein is not affected in AtmKD/- cells or by ATM kinase inhibitor 
[Fig. 3-3E]. Together these data suggests that Atm KD protein blocks removal of Top1cc. 
Top1cc can be removed in both replication-dependent and -independent manners [see 










Figure 3-2:  Atm
KD/-








 immortalized MEFs (iMEFs) to A.) gamma-irradiation, B.) 
camptothecin (CPT), C.) Etoposide, D.) Hydroxyurea (HU), E.) Aphidocolin, and F.) Olaparib. 
*P<0.001.G.) Representative images and frequency of sister chromatid exchange (SCE) per chromosome 
for vehicle (DMSO) or CPT (1µM) treated MEFs. Red diamonds point to exchange events .H.) 
Representative Rad51 foci 10 hours after exposure to 5Gy of IR, and the quantification for Rad51 and I.) 
phosphorylated RPA (pT21). Brca1
SF/SF
 cells are homozygous for the S1598F mutation, and are unable to 
recruit Rad51(Shakya, Reid et al. 2011). Scare bar~ 10µm. J.) The frequency of CPT (0.1µM, 2 hour)-
induced Rad51 foci in different cells. The bar graph represents the average frequency of cells with greater 
than 5 foci per cell calculated across 3 independent experiments, and the error bars indicate SEM. All p-
values in this figure were calculated based on two-tailed Student’s t-test assuming unequal variances. 
 
hydrolyzes the tyrosine-DNA linkage, or by 3’ flapases (e.g., XPF, Mus81, Eme1 or SLX1/4) that 
excise the oligonucleotide bearing the conjugated Topo-I polypeptide (Pommier 2009, Rouse 
2009), creates a single strand gap, which is filled in and ligated. During DNA replication, Top1cc 
is recognized upon encounting with replication forks, which promotes fork regression. The 
regressed fork could be substrates for structure specific endonucleases (e.g. Mus81 or SLX1/4), 
which cleave the fork structure and generate DSBs. The DSBs is  subsequently repaired by the 
homology-dependent repair (HDR) The double holiday junction intermediates formed during 
HDR can be dissolved by Bloom helicase (Blm) to create non-crossover (NCO) or resolved by 
nucleases (e.g. SLX1/4, GEN1, Mus81, Eme1) to generate both crossover (CO)  and NCO 
products(Chan and West 2014). The CO event could be conveniently scored as a sister 
chromatid exchange (SCE). 
In a previous study on human cancer cell lines, ATM kinase inhibitor reduced CPT 
induced SCEs (White, Choi et al. 2010). Consistent with this findings, we observed that ATM 
kinase inhibitors (K55933, 15µM) reduced CPT-induced SCEs in Atm+/-, but not Atm-/-, MEFs 
[Fig. 3-2G]. Moreover we observed that CPT (1µM) induced robust SCEs in Atm+/- and Atm-/- 
MEFs, but not in AtmKD/- MEFs [Fig. 3-2G]. Together these results suggest that the presence of 
catalytically inactive Atm protein prevents CPT-induced CO. Yet ATM kinase inhibitor did not 




by skewing holiday junction resolvases (e.g., Mus81, SLX4/1 or GEN1) (White, Choi et al. 2010) 
[Fig. 3-2G]. Next we measured DNA end resection, the first step of HDR, by the formation of 
phosphorylated-RPA (pRPA-T21) and Rad51 foci. While ionizing radiation (IR) induced 
phosphorylated-RPA (T21) and RAD51 foci were largely abolished in control BRCA1-deficient 
cells (Shakya, Reid et al. 2011), they are readily induced in both AtmKD/- and Atm-/- cells [Fig. 3-
2H, 3-2I], suggesting that Atm KD protein does not block resection or Rad51 filament formation 
upon DSB formation. Meanwhile we found that CPT-induced Rad51 foci were significantly 
reduced in AtmKD/- cells in comparison to Atm-/- or Atm+/- cells [Fig. 3-2J]. This specific defect in 
CPT-induced, but not IR-induced, Rad51 foci formation in AtmKD/- cells suggests that the Atm KD 
protein blocks resolution of Top1cc at a step upstream of DNA resection and HDR.  
 
ATM KD cells are defective in CPT-induced DSB formation, Top-Icc Resolution 
 DSB is an obligate intermediate for HDR dependent repair of Top1cc. Given the defects 
in CPT-induced SCEs and Rad51 focus formation in AtmKD/- cells, we measured the levels of 
CPT-induced Ser139 phosphorylated H2AX (-H2AX), a marker for DNA DSBs. Two hours after 
0.1µM CPT treatment, -H2AX foci and -H2AX protein accumulate in Atm+/- and Atm-/- cells, but 
not in AtmKD/- cells or Atm+/- cells treated with ATM kinase inhibitor [Fig. 3-3A, 3-3B]. We note 
that CPT-induced phosphorylation of RPA at threonine 21 (T21), a site that is primarily 
phosphorylated by ATR/DNA-PKcs and a marker for ssDNA (Marechal and Zou 2015), is not 
affected in AtmKD/- cells[Fig. 3-3B], suggesting that extended CPT-induced ssDNA could be 
generated independently of DSBs. Consistent with the lack of DSBs specifically, CPT (0.1µM) 
increased alkaline comet tail length [Fig.3-3C], an indicator of ssDNA breaks, in all three 
genotypes, but no significant increase in neutral comet tail length, a measure of DSBs, in 
AtmKD/- cells as it did in Atm+/- and Atm-/- cells [Fig. 3-3C]. Baseline neutral comet tails are longer 







 MEFs cannot generate CPT induced DSBs and accumulate TopI-cc 
A.) Representative images and quantification of CPT-induced γH2AX foci (0.1µM CPT for 2 hours). The 
dot plot represents data collected in three biological replicates with over 200 nuclei quantified per 
genotype per condition. Scale bar ~10µm. B.) Western blots for γH2AX, p-RPA (T21), p-KAP1(S824) of 
cells treated with either Vehicle (-, DMSO) or CPT (+, 0.1µM) for 2 hours. ATM inhibitor (15µM, Ku55933) 
was added 1 hour prior to CPT/vehicle treatment if needed. C.) Quantification of Neutral COMET tail 
lengths of cells treated with Vehicle (-, DMSO) or CPT (+, 15µM) for 1 hour. Two replicates of the 
experiments were performed with over 50 comets quantified for each. D.) In-vitro Complex of Enzymes 
(ICE) assay probing for Top-I (top panel) and radiolabeled mouse genomic DNA (lower panel). The 
amounts (in g) of genomic DNA loaded on each row are indicated on the left of the top panel. This is the 
representative result from at least 3 independent experiments.  E.) Western blot of whole-cell lysates 
collected from MEFs treated with indicated concentrations of CPT for 2 hours. 
 
Atm-/- > Atm+/- cells [Fig. 3-3C], correlating with their levels of spontaneous genomic instability. 





ATM KD blocks structure-specific nuclease activity in a MRE11-dependent manner 
 During replication, CPT-induced DSBs can be generated by direct “run off” of the 
replication polymerase at the single-stranded DNA break or by endonucleases that process the 
stalled replication forks or reversed fork structures as previously revealed by crosslink agents 
(Zhang and Walter 2014). SLX4 is a scaffold protein that interacts with three nucleases, SLX1, 
Mus81, and XPF(Rouse 2009), which all have in vitro nuclease activity consistent with fork 
cleavage. Among them, XPF nuclease forms an obligate dimer with ERCC1. We observed that 
CPT-induced DSBs are also significantly reduced in Slx4-/- MEF and, to a much lesser extent, in 
Mus81-/- MEFs, but not in Ercc1-/- MEFs, suggesting that SLX4/Mus81 and potentially SLX1, but 
not XPF, might function in the same pathway suppressed by Atm KD protein [Fig. 3-4A]. 
Accordingly ATM kinase inhibitor completely abolished the residual CPT-induced -H2AX in 
Slx4-/- MEFs [Fig. 3-4A]. Notably cells deficient for SLX4, Mus81, or ERCC1, all display reduced 
levels of CPT-induced T21p-RPA [Fig. 3-4A]. The loss of CPT-induced pRPA, but not H2AX, 
foci in Ercc1-/- cells, together with the reduction of CPT-induced H2AX, but not pRPA, in AtmKD/- 
cells, suggests that CPT can induce ssDNA breaks and DSBs through independent 
mechanisms. In this context, SLX1/4, Mus81 and XPF/ERCC1 all have 3’ flapase activity which 
can directly cleave the Top1cc to generate ssDNA gaps (Rouse 2009)[Fig. 3-4A]. But only 
SLX4/SLX1 and Mus81 have the 5’ flapase activity and ability to cleave the cruciform structures 
and are implicated in cleavage of DNA crosslinks or Holliday junction structures (Rouse 2009, 
Clauson, Scharer et al. 2013). Finally, complete deletion of Mre11 (Mre11-/-) rescued the CPT-
induced DSBs in the presence of ATM kinase inhibitor [Fig. 3-4B], suggesting that the KD ATM 
is recruited by the MRN complex to DNA, where it blocks CPT-induced DSB formation. Notably, 
nuclease-deficient MRE11 is able to form a stable complex with NBS1 and Rad50 (Buis, Wu et 
al. 2008) but did not rescue CPT-induced DSBs in cells treated with ATM kinase inhibitor [Fig. 





Figure 3-4: Mre11-dependent recruitment of Atm KD protein blocks resolution of Top1cc by 
SLX4/Mus81/SLX1 nuclease 






 MEFs. Cells were either treated 2 hours with Vehicle (-, 
DMSO) CPT (C, 0.1µM), or pre-treated 1 hour with 15µM Ku55933 prior to CPT treatment (CA). LE- Long 













immortalized MEF was stably infected with retrovirus expressing 
ER-CRE- IRES-hCD2, MACS purified for hCD2+ cells and then induced with 4OHT (200nM) for 48 hours. 
The PCR confirmed the efficient conversion of the Mre11 conditional allele to the null allele as previously 
described (Buis, Wu et al. 2008). For the western blots, cells were either treated 2 hours with Vehicle (-, 
DMSO) CPT (C, 0.1µM), or pre-treated 1 hour with 15µM Ku55933 prior to CPT treatment (CA). F) 
Representative images of the DNA combing assay Cells were incubated 30 minutes with 25µM IdU, 
followed by 250µM of CldU along with either vehicle (DMSO) or CPT (1µM). The dot plot represents the 
summary of two independent experiments. *P<0.0001. 
 
for the recruitment of ATM to CPT-induced lesions during replication. Notably, ATM inhibitors 
only partially reduced CPT-induced DSB in WT cells, yet completely abolished CPT-induced 
DSBs in Mre11-nuclease defective cells [Fig. 3-4B], suggesting that the nuclease activity of 






Figure 3-5: Working model for ATM KD blockage of DSB formation upon Top-I conjugation 
In non-proliferating cells, Top1cc is removed by TDP1 or 3’ flapases to 
generate single stand breaks, which is repaired by PARP1 and Ligase3 mediated pathways. In 
replicating cells, Top1cc collision with replication forks leads to fork reversal as well as strand 




 In this section, we identified novel phosphorylation-dependent structural functions of 
ATM in HR, the processing of Topo1 lesions, and replication. AtmKD/- MEFs displayed 
hypersensitivity to CPT compared to Atm+/- and Atm-/- cells due to Top1cc accumulation 
resulting from the loss of DSB formation upon CPT treatment. Moreover, we show that ATM KD 
protein, when recruited to the replication fork by MRE11, blocks SLX4/SLX1- and Mus81-
mediated cleavage of Top1cc lesions during replication. These results identify novel functions of 
ATM upstream of the formation of DNA DSBs, and provide additional insight into previously 
unknown structural functions of ATM in DNA repair. 
 While a direct effect of ATM KD lesions on HDR cannot be excluded, the slow fork 
progression in ATM KD cells might indirectly compromise HDR as measured by the DR-GFP 
reporter HR measured by DR-GFP is suppressed in Atm-/KD cells but not in Atm-/- cells. But 
phosphorylated RPA and Rad51 foci are only reduced in CPT treated, but not IR treated Atm-/KD 




Rad51 foci and SCEs in Atm-/KD cells, why I-SceI nuclease induced “clean” DSBs could NOT be 
efficiently repaired by HR in the AtmKD/- cells remains elusive. One possibility is that ATM KD 
suppresses a later step of HR, such as the resolution of the holiday junctions by BLM and other 
nucleases. Notably, some of the nucleases contribute to holiday junction resolution (e.g. Mus81 
and SLX1/4) are also implicated in the strand cleavage upon ICL or possibly also Top1cc blocks 
(Rouse 2009, Zhang and Walter 2014). It is tempting to speculate that catalytically inactive ATM 
might block the same nuclease(s) to suppress CPT induced DSBs and HR. Alternatively, the 
slow progression of the replication forks in the Atm-/KD cells might indirectly reduce HR, as 
measured by DR-GFP, by reducing the number of HR compatible cells in culture.   
 Intermolecular auto-phosphorylation has been described for several PI3KK family 
members, including ATM, DNA-PKcs and ATR (Bakkenist and Kastan 2003, Dobbs, Tainer et 
al. 2010, Liu, Shiotani et al. 2011, Jiang, Crowe et al. 2015). Using a mouse model expressing 
the kinase dead DNA-PKcs protein, we showed that DNA-PKcs protein physically blocks end-
ligation during NHEJ at the DNA ends in a Ku dependent manner and requires auto-
phosphorylation for end-ligation (Jiang, Crowe et al. 2015). Here our data suggest that in a 
similar manner, ATM protein blocks the Top1cc induced strand cleavage at the replication fork 
in Mre11-dependent fashion that is regulated by its auto-phosphorylation. Our data also further 
suggests that Mre11 nuclease activity might have a role in releasing ATM KD from the 
replication fork. In this context, Sae2 and Mre11 have been found to limit the DNA damage 
responses elicited by Tel1 and Mec1 – yeast homolog of ATM and ATR respectively (Clerici, 
Mantiero et al. 2006, Chen, Donnianni et al. 2015). Therefore it is tempting to suggest that auto-
phosphorylation of PI3KKs might have a common function in promoting their release from their 
respective activation partners (Ku for DNA-PKcs, Mre11 for ATM), regulates specific repair 
events (NHEJ for DNA-PKcs, replication for ATM) and terminate the DNA damage responses. 
In the AtmKD/- cells, this replication defect, combined with the lack of ATM-mediated checkpoint 




Chapter 4 - Structure-kinase function of ATM in tumor suppression, and the mutational 
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Background and Significance 
 
 Germline expression of ATM KD led to unexpected embryonic lethality in mice, and cells 
expressing ATM KD displayed hypersensitivity to CPT and defects in replication. However, due 
to the early embryonic lethality of ATM KD mice, whether the ATM KD still retains tumor 
suppression function in vivo remained undefined. To address this, we generated mice 
conditionally expressing ATM KD in hematopoietic stem cells (HSCs) using Vav-cre. Strikingly, 
AtmKD/- mice developed aggressive thymic lymphomas with higher penetrance and kinetics 
compared to Atm-/- mice. Detailed genomic analyses identified more frequent deletion of PTEN 
in AtmKD/- thymic lymphomas compared to the null. Additionally, stimulated AtmKD/- T-cells were 
hypersensitive to a combination treatment of CPT and PARP inhibitor, providing insight into a 
therapeutic regimen to selectively treat tumors with ATM KD compared to the null. Therefore, 
the expression of a catalytically inactive ATM is more oncogenic than ATM null, and can be 
selectively treated using CPT and PARP inhibitors to exploit ATM KD blockage of Top-Icc 
removal via DSB formation mechanism. 
 Somatic mutations of ATM have been identified in human tumors, but the types of 
mutations and their functional consequences that occur in both germline A-T and somatic 
mutations identified in human tumors are not well understood. To address this, here we report 
that cancer-associated ATM mutations are highly enriched (>70%) for missense mutations 
clustering within the kinase domain, while A-T-associated germline ATM mutations are 
predominantly truncation mutations that abrogate protein expression. Several tumor-associated 
missense mutations identified within the kinase domain are predicted to affect residues directly 
involved in the kinase activity of ATM, suggesting the expression of KD ATM in human tumors. 
Together, these findings provide a mechanism for the diverse cancer risk associated with 




ATM protein could be preferentially targeted by Topoisomerase I inhibitors, a class of drugs that 




Expression of kinase-dead ATM is more oncogenic than complete loss of ATM  
 Although Atm-null animals develop normally(Barlow, Hirotsune et al. 1996), mice 
harboring germline kinase-dead (KD) Atm mutations (AtmKD/KD or AtmKD/-) (equivalent to N2875K 
& D2889A of human ATM, N2875K was found twice in TCGA cases) undergo embryonic 
lethality (Daniel, Pellegrini et al. 2012, Yamamoto, Wang et al. 2012), explaining the lack of 
kinase domain missense mutations in live-born A-T patients. Nevertheless, it remains unclear 
whether the kinase-dead ATM lesions can promote malignant development.  Therefore, to 
compare the oncogenic potential of Atm-KD vs Atm-null mutations, we generated Vav-
Cre+AtmC/KD(VKD) and Vav-Cre+AtmC/C (VN, N for null) mice, in which the Vav-promoter drives 
expression of Cre-recombinase in hematopoietic stem cells (HSCs), leading to deletion of the 
conditional ATMC allele in all hematopoietic cells including lymphoid cells [Fig. 4-1A].  . 
Thymocytes from VKD or VN mice display the classic spectrum of T cell developmental defects 
characteristic of ATM-/- mice; namely, reduced CD3 surface expression and partial blocks at the 
CD4+CD8+ double-positive (DP) to CD4+CD8- and CD4-CD8+ single-positive (SP) T cell 
transitions (Borghesani, Alt et al. 2000) [Fig. 4-1B].  Similarly, VKD and VN B cells show a ~50% 
reduction in class switch recombination (CSR) efficiency [Fig. 4-1B], confirming efficient Atm 
inactivation in VKD and VN lymphocytes. Notably, the frequency of double-negative 3 (DN3) T 
cells is increased 1.5 fold in VKD mice, but not in VN or ATM-/- mice [Fig. 4-1B, 4-1C]. The DN3 











Figure 4-1: Lymphocyte development and characterization of the VKD and VN mice 
A.) Southern Blot for the Atm conditional vs deleted allele in kidney, bone marrow, splenocytes, 
thymocytes and activated splenic B cell (CD43
-
, LPS stimulated) of a representative VN mouse, indicating 
complete deletion of Atm in lymphoid lineage. KpnI-digested genomic DNA probed with ATMCKO3’ probe 
B.) FACS analyses show normal B cell development and both class switch recombination and T-cell 
development defects in B cells from VN and VKD mice similar to those observed in Atm
-/-
 mice. LPS+IL-4 
column show the frequency of IgG1
+
 B cells after the CD43- purified splenocytes were activated  by LPS 
and IL-4 for 4.5 day. CD44 and CD25 double staining was performed on live gated Double Negative (DN) 
thymocytes defined as negative for surface staining of CD8, CD4, CD19, TCRɤδ and Ter119. C.) CSR 
efficiency. Bar graphs represent %IgG1+ cells collected at day 4.5 after LPS, IL-4 stimulation. Error bars 
indicate SEM. *P<0.05 between ctrl and each of the 3 other genotypes per two-tailed Student’s t-tests 
assuming unequal variances. D.) The total thymocyte counts from 4-8 week old VN (n=3), VKD (n=3) 
mice. E.) Telomere FISH analyses of metaphases spread from Con A-stimulated T-cells (3 days). Bar 
graphs represent the average number of cytogenetic aberration per metaphase (MP) from two 
independent mice per genotype. The error bars indicate SEM. 
 
 
analyses revealed cytogenetic abnormalities in 37% VKD, 27% VN and 3% Atm+/+ Con A-
stimulated peripheral T cells [Fig. 4-1E]. Consistent with previous reports in activated B cells 
(Yamamoto, Wang et al. 2012), the most dramatic increases of the genomic instability in the 
VKD T cells are chromatid breaks, suggestive of replicative/post-replicative repair defects [Fig. 
4-1E]. As a result of the DN3 block, the total thymocyte number was reduced 66% in 6-week-old 
VKD mice compared to age-matched VN littermates [Fig. 4-1D]. Despite reduced thymocyte 
numbers, VKD mice succumbed to thymic lymphomas 35.5 days earlier than littermate control 
VN mice [Fig. 4-2A]. Overall 75% of VKD and 56% VN mice died of lymphomas within 400 days 
[Fig. 4-2B]. While VN mice, like Atm-/- mice, uniformly succumbed to CD3low immature thymic 
lymphomas, 2 of the VKD mice (8%) developed B220+CD43+IgM- pro-B cell lymphomas [Fig. 4-
2B, 4-2E, 4-2F]. The thymic lymphomas from VKD and VN mice share a common 
immunophenotype (CD3low, CD4+CD8+ DP or immature CD8+ SP) and all contain clonally 
rearranged TCRβ loci [Fig. 4-2D]. Comparative genomic hybridization (CGH) on four VKD and 
one VN T cell lymphomas identified common copy number alterations characteristic of ATM-/- 
thymic lymphomas (Zha, Bassing et al. 2010, Jiang, Lee et al. 2015), including frequent trisomy 












Figure 4-2: Expression of Atm KD protein alone in hematopoietic stem cells (HSCs) is more 
oncogenic than complete loss of Atm in mouse models 
A.) Kaplan-Meier (K-M) survival curve of VN (n=18) and VKD (n=24) mice. The red and blue dots denote 
thymic lymphomas from the VN and VKD cohorts, respectively. The yellow dots denote the B cell 
lymphomas in the VKD cohort. The T1/2 for thymic lymphoma development is 139.5 days (VN) and 104.0 
days (VKD) respectively. The asterisk marks the difference in T1/2 of thymic lymphoma development 
between the two cohorts. *P=0.03 per Mantel-Cox/log-rank test. B.) The overall frequency of B and T cell 
lymphomas in VN, VKD cohort monitored for 400 days. C.) FACS analyses of thymocytes harvested from 
VN (red bracket) and VKD (blue bracket) mice with thymic lymphomas. The dash line marks the level of 
surface TCRβ expression in control thymocytes D.) ) Southern blot analyses of thymocyte DNA digested 
with EcoRI and probed with TCRJβ1.6 and TCRJβ2.7 probes. Marker: Molecular Weight Marker. Ctrl: 
Kidney DNA harvested from a VavCre- Atm
C/KD 
mouse, GL-Germline. E.) FACS analyses of the 
splenocytes from control and two VKD mice with B-cell lymphomas. F) Southern blot analyses of 





telomeric ends [Fig. 4-3A]. Also, Pten deletions, which are associated with ~25% of Atm-/- 
lymphoma (Zha, Bassing et al. 2010), were observed in all four VKD tumors but not in the VN 
tumor [Fig. 4-3A, 4-3B]. Western analyses of additional tumors revealed lack of Pten protein 
expression in all, but one, VKD tumor [Fig. 4-3C].  In contrast, most VN tumors retained residual 
Pten expression, and the only Pten-expressing VKD tumor (6684) lacked expression of the ATM 
KD protein [Fig. 4-3C].  Interestingly, Pten loss, which is known to synergize with Atm or Tp53 
deficiency in lymphomagenesis, has been reported to occur in early lymphoid progenitors before 
TCRβ rearrangement in Tp53-/- T cells, as 10 week thymocytes from Tp53-/- mice contain 
oligoclonal T cells with diverse TCRβ rearrangements yet identical PTEN deletions (Dudgeon, 
Chan et al. 2014). Based on these findings, we propose that, unlike complete ATM loss, 
expression of catalytically-inactive ATM further increases genomic instability, leading to frequent 
Pten inactivation in lymphoid progenitors and early onset lymphomagenesis.  
 AtmKD/- MEF cells are hypersensitive to CPT and PARP inhibitor Olaparib compared to 
Atm null cells [Chapter 3, Fig. 3-2F]. Additionally, cells resolve CPT-induced Top-1ccs via two 
pathways- one that generates a DSB intermediate, while the other is exclusively SSB. DSB 
generation requires nucleases SLX4/MUS81 which is blocked in the presence of KD ATM in a 






Figure 4-3: ATM KD tumors undergo more frequent loss of Pten compared to ATM null 
A.) CGH analyses of 1 VN, and 4 VKD tumors. The Y axis is Log ratio (base 2) of tumor/kidney from the 
same mice. The red arrow heads indicate trisomy 15 and the green error heads pointed to the deletion 
around Pten gene. Each chromosome is demarcated by gray lines, and the chromosome numbers are 
marked at the top of the CGH panels. B.) Expanded copy number analyses of around the Pten gene on 
mouse chromosome 19 (mm8: 32,779,983-32,908,796). The y-axis is the natural log ratio of tumor/kidney 
from the same mice. Log ratio of -0.67 (dotted line) indicate heterozygous deletion. C.) Western blot of 
Pten, total Atm and β-actin for Atm
+/+






Figure 4-4: VKD T-cells are hypersensitive to CPT and PARP inhibitor combination treatment 
Relative survival of ConA-stimulated mature T-cells harvested from the spleen of control (ctrl) VN, VKD 
mice. The T-cells were harvested from the spleen, and continually stimulated with ConA for 72 hours. The 
cells were treated with drugs for 48hours after incubation with only ConA for 24 hours. (Right) EC50 plot 
for the VKD T-cells. Concentrations at which the relative survival was 50% for CPT and PARP inhibitor 
single treatments are shown on the X and Y axis, respectively. The green dot represents the 
concentration for both drugs at which there was 50% relative survival for the dual CPT/PARP inhibitor 
treatment. 
 
mediated by LIGASE3 and PARP [Chapter3, Fig. 3-5]. We therefore hypothesized that VKD 
cells are hypersensitive to the inhibition of a combination of CPT treatment with PARP inhibition. 
Indeed, ConA stimulated mature T-cells from VKD mice are synergistically hypersensitive to 
dual CPT and Olaparib treatment compared to wildtype and VN cells [Fig. 4-4]. We therefore 
propose that, despite the increased kinetics and incidence of tumors with ATM KD mutations 
compared to wildtype and ATM null, KD tumors are selectively hypersensitive to a combination 
of CPT and PARP inhibitor treatment, and demonstrate a therapeutic intervention method to 





Missense mutations in the kinase domain of ATM are enriched in human tumors 
~87% of A-T-associated ATM lesions (447 unique mutations from >1000 cases) are 
truncation or frame-shift mutations [Fig.4-5A], consistent with the observation that ATM protein 
is undetectable in most A-T patients (Becker-Catania, Chen et al. 2000). In contrast, we found 
that among the 286 unique non-synonymous somatic mutations of ATM identified from 5,402 
cancer cases in The Cancer Genome Atlas (TCGA), only 25% are truncation/frame-shift 
mutations and 72% are missense mutations [Fig.4-5A]. Furthermore, cancer-associated ATM 
missense mutations are clustered primarily in the kinase domain (AA2711-2962 of human 
ATM), ~2.5-fold over expected [Fig. 4-5B], while both cancer- and A-T- associated 
truncation/frameshift mutations are distributed throughout the entire ATM protein [Fig. 4-5B]. 
Together, these findings suggest a significant subset of the cancer-associated ATM mutations is 
functionally distinct from those implicated in A-T.  
To determine the functional consequences of the ATM kinase domain mutations, we 
performed homology modeling of human ATM kinase domain using the crystal structure of 
human mTOR (PDB 4JSP)(Yang, Rudge et al. 2013), another PI3K-related protein kinase, as 
modeling template(Yang, Rudge et al. 2013). Primary sequence alignment suggests that the 
kinase domain of ATM and mTOR are highly conserved with a sequence identity of 30% [Fig. 4-
6A]. The model predicted that residues K2717, D2720 and H2872 of human ATM are directly 
involved in ATP binding. In particular, residue H2872 binds the -phosphate of ATP, while amino 
acids D2870, N2875 and D2889 coordinate Mg+ metal ion, which is essential for ATM kinase 
activity [Fig.4-6B, 4-6C, 4-6D]. Within the ribbon structure, a subset of the cancer-associated 
ATM missense mutations are highlighted in red [Fig. 4-6B, 4-6C].  Based on the structure, we 
conclude that many cancer associated ATM mutations, including D2720N (2 cases), D2721N 
(1), L2722M (2), D2725G (1), as well as H2872R (1), N2875S/K(2), L2885H(1), L2890R (1) and 






Figure 4-5: Cancer associated ATM mutations are enriched for kinase domain missense mutations  
A.) Classification of the unique and non-synonymous mutations reported for A-T patients in the Leiden 
open variable database (http://chromium.lovd.nl/LOVD2/home.php?select_db=ATM) (n=447) or identified 
as somatic mutations from 5402 unique cancer cases sequenced by TCGA (n=286). “Others” category 
includes splice-site and stop codon mutations. B.) A heatmap for the frequency of cancer-associated 
truncation and frameshift mutations (upper panel) or non-synonymous missense mutations (lower panel) 
along human the ATM polypeptide obtained using Gaussian kernel based analyses (online method). 
Hotter color indicates denser mutation distribution. The shadowed curve (bottom panel) reflects fold of 
mutation over expected mutation frequency, calculated by Gaussian kernel method. The confidence 
interval (shadow) is estimated by fitting binomial distribution (online method). The dash line at 1 
represents the expected rate of mutations. The x-axis is the amino acid number (from 1-3056) along 
human ATM protein. 
mutations on the outer surface of the ATM kinase domain (e.g. R3008H) may also interfere with 
kinase activity.  
 
Human cancer cell lines that harbor ATM missense mutations display defects in CPT 
induced DSBs formation and are also hypersensitive to CPT.  
 Based on information in the Cancer Cell Line Encyclopedia (CCLE) (Broad Institutes), 
we identified a panel of human cancer cell lines with potential KD mutations [Fig.4-7A]. The 









Figure 4-6: Missense ATM mutations identified in human tumors affect the kinase domain 
A.) Permutation analyses of actual truncation or missense mutation frequencies within the ATM gene or 
within the ATM kinase domain over the expected mutation frequency based on the size of the gene and 
the frequency of non-synonymous mutation. The dash line marks the expected mutation rate B.) The 
distribution of truncation/frame shift mutations in A-T patients. The blue-shaded region represents the 
95% confidence interval  C.) Sequence alignment of human ATM with mouse ATM and human mTOR. 
The sequences were aligned with ClustalW and the resulting output was rendered with ESPript. The AAs 
conserved between ATM and mTOR are indicated with red stars. D.) Superposition of the human ATM 
model (yellow) and the crystal structure of human mTOR (blue). Mutations conserved between ATM and 
mTOR are shown in red. The active site architecture of human ATM. ATP is shown in red, Mg
2+
 ion is 
shown in purple, the catalytic residues from ATM are shown in blue and the substrate is colored black.  
for ATM protein and IR induced phosphorylation of Kap-1, a prominent substrate of ATM [Fig.4-
7B]. Notably CPT (100nM) induced -H2AX was significantly reduced in those cell lines in 
comparison to the ATM+/+ HBL2 cells [Fig. 4-7C]. Both Granta519 and HBL2 are MCL cell lines 
with IgH-CyclinD1 translocation and ectopic expression of CyclinD1. Granta519 cells that 
express a catalytically inactive ATM are significantly more sensitive to CPT than HBL2. [Fig.4-
7D]. Together these results suggest that human cancer cell lines expressing catalytically 




 Our findings reveal that cancer-associated ATM lesions are predominately missense 
mutations that compromise the kinase activity of ATM. We further show that expression of 
catalytically-inactive ATM protein is more oncogenic than simple loss of ATM. This is in part due 
to increased genomic instability in AtmKD/- HSCs, which leads to frequent deletion of PTEN. 
Moreover, the majority of ATM mutations in human cancers reported in the TCGA are missense 
mutations that are highly enriched in the PI3K domain, and human tumor lines expressing 
mutant ATM are hypersensitive to CPT, similar to that observed in AtmKD/- MEFs and T-cells. 





Figure 4-7: ATM mutated human tumor lines are also hypersensitive to CPT. 
A.) Table with the annotated ATM mutations in human cancer cells. B.) Western blots of total cell lysates 
harvested from the indicated human tumor lines for ATM (upper), and pKap1 (lower) with (+) or without (-) 
5Gy Irradiation (IR). C.) CPT Sensitivity assay for two Mantle Cell Lymphoma (MCL) cell lines HBL-2 
(ATM
wt/wt
) and Granta519 (ATM
R2832C/-
). D.) Western blot of human tumor lines treated for 2 hours with 





and suggest the use of Topo1 inhibitors- a class of drugs already available in the clinic, in the 
treatment of ATM mutated cancers. 
 The functional significance of many newly emerging missense mutations of ATM from 
cancer genomic analyses is not fully understood. Using genomic, structural modeling and 
mouse genetics tools, we showed that missense mutations in the ATM kinase domain leading to 
the expression of a kinase dead ATM protein are prevalent in human cancer, more oncogenic 
than complete loss of ATM, and most importantly confer a hypersensitivity to Topo1 inhibitors. 
ATM is already routinely included in cancer genetic panels. Our findings suggest that patients 
carrying tumor with kinase inactivating mutations of ATM would likely benefit from Topo1 
inhibitor, a class of drug that is already available in the clinic. In addition, our study also 
identified an auto-phosphorylation dependent structural function of the ATM protein during DNA 
replication that is “upstream” of the DSBs. We further showed that this role of ATM in replication 
is relatively specific for Top1cc-induced, but not to HU or Aphidicolin-induced, replication fork 
stalling and require Mre11 protein, but not its kinase activity. Together, this novel function of 
ATM in replication expands the repertoire through which ATM suppresses tumorigenesis and 
has implications on the mechanism of replication dependent repair, cancer etiology and cancer 
treatment. 
 ATM suppresses tumorigenesis through its function in checkpoint activation and repair. 
The role of ATM during checkpoint activation is primarily mediated by its kinase activity and is 
abolished by either the null or the KD mutations. ATM null cells primarily accumulate 
chromosomal breaks, consistent with a major role of ATM kinase in pre-replication DNA repair 
especially NHEJ (Franco, Gostissa et al. 2006). Accordingly, A-T patients or ATM null mice are 
mostly affected by lymphoid malignancies owing to the important role of NHEJ in lymphocyte 
specific DSB repair and somatic mutations of ATM in lymphoid malignancies (e.g. MCL, CLL 




Stewart et al. 2002, Bea, Valdes-Mas et al. 2013). In chapter 3, we show that ATM KD 
suppresses replication dependent repair of Top1cc lesion and a subset of HR in addition to 
NHEJ. Defects in HR, such as mutation in BRCA1 or 2 genes, confer increased risk for breast, 
ovarian or pancreatic cancers, in which recurrent ATM mutations, especially frequent missenses 
mutations, were also identified (Roberts, Jiao et al. 2012, Cremona and Behrens 2014). Thus, 
our findings suggest that the variable risk to diverse type of cancers might be explained by how 
specific ATM mutations affect the different repair pathways. It also suggests that the oncogenic 
potential of the ATM mutations might correlate with the level of catalytically inactive ATM protein 
as higher expression of KD ATM would likely be more oncogenic, and might be modulated by 
interaction between the mutated ATM and MRN complex.  
 The selective hypersensitivity of AtmKD/- cells to Topo1 inhibitor provides a potential 
targeted therapy for ATM mutated cancer. This result also suggests that AtmKD/- cells would be 
sensitive to other drugs targeting Top1cc removal and repair pathways, including the PARPs 
which facilitates stand ligation and TDP1 that cleaves the Top1cc (Pommier 2009, Murai, Zhang 
et al. 2014). Indeed, a previous study showed that ATM mutated Grant519 cells are 
hypersensitive to PARP inhibitors (Williamson, Kubota et al. 2012) and we also found that Atm 
KD/- T cells are hypersensitive to the combination of low dose PARP inhibitors and CPT [Fig. 4-4]. 
AtmKD/- cells confer selectively sensitivity to Topo1 inhibitor, but not HU and APH [Chapter 3, 
Fig. 3-2D, 3-2E]. We found that ATM KD protein prevent CPT induced DSBs. In addition to 
Topo1 inhibition, interstrand crosslink (ICL) agents (e.g. mitomycin C, cisplatins) also stimulate 
fork cleavage and generate replication dependent DSBs as the intermediates(Zhang and Walter 
2014).  Therefore, ICL agents might also be beneficial for patients with Atm mutated cancers. 
Together these findings further expand the treatment options for patients with ATM mutated 
cancers. One of the next challenges would be how to reliably identify actual ATM KD mutations 
in the clinic, as sequence analysis is not sufficient to predict ATM function in most cases. In this 
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Background and Significance 
 
Mature B-cell lymphomas represent 85% of non-Hodgkin Lymphomas (NHL) and many 
harbor characteristic chromosomal translocations involving the immunoglobulin (Ig) loci. ATM is 
frequently inactivated in human B-cell NHL. Among all B-NHLs, MCL has the highest frequency 
of bi-allelic inactivation of ATM (Bea, Valdes-Mas et al. 2013). MCL is a mature B-cell 
lymphoma composed of small to medium-sized lymphocytes with frequent (~30%) involvement 
of the gastrointestinal tract. The variable regions of the Ig are unmutated in the majority of MCL 
cases, consistent with a pre-GC origin. MCL is characterized by deregulated expression of D-
type cyclins, especially CyclinD1, via the characteristic t(11;14) chromosomal translocation that 
joins CyclinD1 with the active Ig-heavy chain gene (IGH) promoter and enhancer. Yet, ectopic 
expression of wild type (WT) CyclinD1 is insufficient to induce MCL in mouse (Bodrug, Warner 
et al. 1994, Lovec, Grzeschiczek et al. 1994), implying additional genetic alterations are 
necessary. Effective treatment for MCL is not available, and animal models recapitulating 
molecular features of human MCL are yet to be developed. In addition, the role of ATM 
inactivation in B-cell lymphomagenesis is not yet well understood. This is in part due to the lack 
of ATM-deficient B-cell lymphoma model, as germline ATM-null mice develop early, aggressive 
thymic lymphomas.  
In this chapter, we report that early and robust deletion of ATM in precursor/progenitor 
B-cells causes cell-autonomous, clonal mature B cell lymphomas of both pre- and post-germinal 
center (GC) origins. Unexpectedly naïve B cell specific deletion of ATM is not sufficient to 
induce lymphomas in mice, highlighting the important tumor suppressor function of ATM in 
immature B cells. While EµCyclinD1 is not sufficient to induce lymphomas, EµCyclinD1 
accelerates the kinetics and increased the incidence of clonal lymphomas in ATM-deficient B-




morphological features of human MCL. This is in part due to CyclinD1-driven expansion of ATM-
deficient naïve B cells with genomic instability, which promotes the deletions of additional tumor 
suppressor genes (i.g. Trp53, Mll2, Rb1 and Cdkn2a). Together these findings define a 
synergistic function of ATM and CyclinD1 in pre-germinal center B-cell proliferation and 





Mouse models with B-cell specific deletion of ATM 
To circumvent early lethality due to thymic lymphomas in germ line Atm knockout mice 
(Atm-/-), we generated B-cell specific deletion of Atm using CD21Cre, CD19Cre, or Mb1+/Cre in 
combination with the ATM conditional allele (ATMC) (Zha, Sekiguchi et al. 2008). CD21Cre allele 
(Kraus, Alimzhanov et al. 2004) mediates specific and robust ATM deletion in IgM+ naïve B-cells 
and CD19Cre+ATMC/C (Rickert, Rajewsky et al. 1995) results in ATM deletion ranging from 60% 
in bone marrow pre-B-cells to nearly  100% in naïve splenic B-cells [Fig. 5-1A] Despite efficient 
deletion of ATM in naïve splenic B-cells in both CD21Cre+ATMC/C and CD19Cre+ATMC/C mice as 
evidenced by Southern blot analyses, CSR defects, and genomic instability, none of the 
CD21Cre+ATMC/C (n=23) or CD19Cre+ATMC/C (n=36) mice developed definitive B-cell 
lymphoproliferations in >28 month follow-up period [Fig. 5-1B, C], by which time the bone 
marrow samples were virtually devoid of B-cells.  
Based on this observation and the postulated “early” deletion of ATM in human MCL 
(Jares, Colomer et al. 2007), we focused on Mb1Cre(Hobeika, Thiemann et al. 2006), which is 
the earliest B-cell specific Cre allele available, that leads to specific and robust cre activation in 









 mouse models. 






















(hereafter referred to as M) Mb1+/CreAtmC/C(-)EµCyclinD1- (MA), Mb1+/cre(+)Atm+/+(C)EµCyclinD1+ 
(MD/D) and Mb1+/creAtmC/C(-) EµCyclinD1+ (MAD). First, we confirmed the efficient and specific 
deletion of the ATM gene and protein in splenic B-cells from MA mice by Southern [Fig. 5-2A] 
and Western blotting [Fig. 5-2B] respectively. In B-cells purified from MA mice, irradiation 
induced phosphorylation of Kap-1, an ATM specific substrate (Ziv, Bielopolski et al. 2006), was 
largely abolished confirming the loss of ATM kinase activity [Fig. 5-2C]. Meanwhile, T-cells from 
MA or MAD mice were devoid of the development defects associated with ATM deficiency 
(Borghesani, Alt et al. 2000) – namely reduced surface CD3/TCR expression and reduced 
CD4 or CD8 single positive T-cells in the thymus- consistent with normal ATM function in T-cells 
from MA or MAD mice [Fig. 5-2D] Similarly, myeloid (Gr1+ or CD11b+) and erythroid (Ter119+) 
lineages were also unaffected in the bone marrow and spleen of MA and MAD mice [Fig. 5-2D] 





A.) Southern blot analyses of the Atm locus with genomic DNA harvested from kidney (Kid), thymus 
(Thy), bone marrow (BM), total spleen cells (Spl), LPS/IL-4 stimulated splenic B-cells B.) and Con A 
stimulated splenic T-cells (T).  B) Western Blot analyses for CyclinD1 and ATM in stimulated splenic B 
and T-cells harvested from MD, MA, and MAD mice. C.) Phosphorylation of Kap1 in LPS/IL4 stimulated 
B-cells (day 3) with or without irradiation (IR,10Gy). Protein lysate is collected 2 hours after IR. D.) 
Representative flow cytometry analyses of bone marrow (BM), spleen and thymocytes from Atm
-/-
 as well 
as MA, MAD and MD mice. 
 
















and efficient deletion of ATM in developing B-cells. In the Mb1+/Cre mice, the Cre knock-in 
disrupts the endogenous Mb1/CD79a gene in the targeted allele (Hobeika, Thiemann et al. 
2006). Since Mb1/CD79a is essential for B-cell development and Mb1/CD79a-/- B-cells arrest at 
the pro/pre- B-cell stage (Minegishi, Coustan-Smith et al. 1999, Pelanda, Braun et al. 2002), we 
also confirmed normal B-cell development and spleen cellularity in control MD/D, MA and MAD 
mice (all carrying heterozygous Mb1+/Cre alleles)  and only used Mb1+/Cre for all breeding and 
final tumor cohorts [Fig. 5-2D]. Finally, ectopic expression of CyclinD1 in both B and T-cells was 
also verified in EµCyclinD1+ MD and MAD mice by Western blotting [Fig. 5-2B 
 
B-cell specific deletion of ATM leads to B-cell autonomous lymphomas of both GC and 
non-GC phenotype  
 To determine the role of ATM deficiency in B-cell lymphomagenesis,We followed a 
cohort of MA mice with weekly palpation to identify any abnormal growths. During the 20-month 
follow-up, 12.5% (3/24) of MA mice developed overt splenomegaly and lymphadenopathy, with 
frequent intestinal involvement (67%, 2/3) [Fig. 5-4A]. Flow cytometry analyses revealed mono-
clonal expansion of CD19+ (often B220+) B-cells, which was further confirmed by Southern blot 
analyses that detected clonal IgH rearrangements in all confirmed cases [Fig. 5-3A, B]. In the 
same period, none of the Mb1Cre/+Atm+/+(C/+) mice developed any signs of tumors. At >20 month 
of age, all tumor cohorts were euthanized for end point analyses. One additional MA mouse 
(2023) was found to have a B-cell lymphoma based on clonal IgH rearrangement and histology 
[Fig. 5-3B, C] bringing the lifetime risk for monoclonal lymphoproliferative disease to 4/24 
(16.7%) in MA mice. Histopathologic and immunophenotypic analyses revealed diffuse large B-
cell lymphomas (DLBCL) of splenic or nodal origin in the MA mice, with one manifesting a GC 





Figure 5-3: Clonal B-cell lymphoproliferations in 24 month plus MA and MD/D mice and 
representative flow cytometry analyses of MAD mice 
A) Representative flow cytometry analyses of spleen from tumor bearing MA and MD/D mice. B) 
Southern Blot analyses of DNA harvested from kidney (K) and spleen (S) from MA and MD/D mice. 
Asterisk denotes mouse 2594, which the DNA is partially degraded. Blue arrow heads point to clonal 
rearrangements. GL: Germ line. Probe for the constant region of TCRδ is used as loading control. C) 
Histological analyses of represented MA tumors. 2594 is GC-type DLBCL. The white pulp is expanded 
and effaced by large lymphocytes with centroblastic features and admixed tingible body macrophages. 
The neoplastic lymphocytes express B220 and BCL6 and lack IRF4 expression, the immunophenotypic 
features are indicative of a DLBCL of GC phenotype. 2583 is non-GC type DLBCL. A predominant and 
extensive red pulp infiltrate of large centroblast-like cells is present. The neoplastic lymphocytes express 
PAX5 and IRF4, but lack B220 and BCL6 expression (note: the white pulp component appears to express 
B220), the immunophenotypic features are indicative of a DLBCL of non-GC phenotype. 
 
 [Table 5.1, Fig. 5-3C]. Given the GC and non-GC immunophenotypes, we analyzed the IgH for 




on these data, we conclude that deletion of ATM in early pre-/pro- B-cells leads to infrequent 
mature B-cell lymphomas of heterogeneous cell origins with long latency. These results support 
a role of ATM as a tumor suppressor gene during early B cell development and also highlight 
the need for additional genetic hits.  
 
CyclinD1 overexpression accelerates B-cell lymphoproliferations in MA mice and skews 
lymphomas towards pre-GC origin 
  Among all human B-NHLs, MCL, characterized by ectopic expression of CyclinD1, has 
the highest frequency of bi-allelic inactivation of ATM (Bea, Valdes-Mas et al. 2013). Given the 
early deletion of ATM during MCL development, it was proposed that ATM deficiency might 
increase IgH-CyclinD1 translocation to promote MCL (Bea, Valdes-Mas et al. 2013).  
Alternatively, ectopic CyclinD1 expression might synergize with ATM deficiency to promote 
cellular proliferation at the price of genomic instability to drive B-cell lymphomagenesis. To test 
this, we bred MA mice with EµCyclinD1 transgenic mice to generate the MAD and control MD/D 
mice. At two months of age, B-cell number and B-cell development in MAD mice is comparable 
with MA and MD controls [Fig. 5-2D]. By 20-months of age, 3/18 (16.7%) MAD mice had 
developed overt splenomegaly and lymphadenopathy with occasional intestinal involvement and 
leukemic presentation [Table 5.1, Fig. 5-4B]. The tumor free survival of MAD mice was 
significantly shorter than either MA or MD/D control groups [Fig. 5-4A]. Moreover, at the end-
point analyses (>20 month), 46.6% (7/15) of MAD mice showed clonal B-cell expansions by flow 
cytometry analyses and clonal IgH and Igκ rearrangements by Southern blotting [Fig. 5-4B, D, 
E] bringing the life-time risk for B-cell lymphoproliferations in MAD mice to 55.6% (10/18). This 
is in sharp contrast to the control MD/D mice, which did not develop overt splenomegaly within 
the 20-month follow-up and only 2/12 MD/D mice showed evidence of B-cell lymphoproliferation 





Figure 5-4: MA and MAD mice develop clonal B-cell lymphoproliferations 
A) Tumor-free survival of MA, MAD and MD/D cohorts up to 20 month of age. Number of mice followed in 
each cohort is listed in the parentheses. *P<0.05 per Mantel-Cox/Log rank test for statistical significance. 
B) Lifetime risk for B-cell lymphoproliferations in MA, MAD and MD/D mice. The gray boxes represent 
tumors discovered within 20-month follow-up period and the white boxes represent tumors discovered at 
end-point analyses (> 20-month). C) Representative images of enlarged spleen and lymph node (from 
MAD mice 3468) and small intestine (right, from MA mice 2023). The black arrow heads point to the 
lymph nodes. D) Representative flow cytometry analyses of spleen from tumor bearing MA and MAD 
mice. The postulated tumor populations are indicated with a circle. E) Southern Blot analyses of DNA 
harvested from Kidney (K) and Spleen (S) from MAD mice. Asterisk denotes mouse 3613, in which the 
tumor primarily resided in bone marrow (B). Mouse 3468 has leukemia with significant infiltration in the 
kidney, thus the presence of clonal rearrangements.  Blue arrow heads point to clonal rearrangements. 
Probe for the constant region of TCRδ is used as loading control. Densitometry intensity ratio of 









(M) Diagnosis Organs SHM 
Surface Marker (FACS) IHC 
B220 IgM Others PAX5 BCL6 IRF4 
2594 MA 18 DLBCL S, Ln - +++ + PNA+  ND  + -  
2583 MA 20 DLBCL S ,Ln - + +   +  - + 
2023 MA 25 DLBCL S, Ln 
+ 
(1/710) - -    ND + + 
3465 MA 19 DLBCL S, K 
+ 
(3/710) + + IgD- + - + 
3468 MAD 13 DLBCL 
S,Ln, PB, 
Liv, K - +++ +++   ND  - + 
3710 MAD 23 LPD S - +++ +++ IgD- ND - +/- 
3557 MAD 24 LPD* S 
+ 
(2/710) - +++   +  - +/- 
3613 MAD 16 LPD*♯ S, BM - +++ +++    + - +/- 
4271 MAD 21 LPD*♯ S - + +++   +  - +/- 
4159 MAD 21 LPD*♯ S - + +++    + - +/- 
4161 MAD 21 LPD*♯ S, Ln 
+ 
(1/710) - +++ CD5+  + - +/- 
3560 MAD 24 LPD*♯ S - + +    + - +/- 
3713 MAD 17 LPD♯ S - + + CD5+  + - +/- 
2569 MAD 23 LPD♯ S, Ln - +++ +++    + - +/- 
2012 MD/D 26 DLBCL 
S, Ln, PB, 
K 
+ 
(3/710) +++ +++ IgD- ND - + 
2603 MD/D 24 LPD* S - + +++ CD5lo ND  - + 
Table 5.1: Pathological characteristics of clonal B-cell lymphoproliferations of MD/D, MA and MAD 
mice 
Organ involved: S-spleen, Ln-lymph node, K-kidney, PB- peripheral blood, Liv-liver, BM-Bone marrow. 
IRF4+/- indicates mixed IRF4 expression.*- Red Pulp Infiltration. ♯-Variable mantle and marginal zone 
expansion. ND-Not determined. SHM- Somatic Hypermutation in Jh4 
  
lymphoproliferations had similar immunophenotypes, namely CD19+B220hi/loIgMhi/lo [Fig. 5-3A, 5-
4D]. The B-cell identity of B220 negative lymphoproliferations was further validated by PAX5 
IHC staining [Fig. 5-3C, 5-5] All tumors were CD21/35-CD23- [Fig. 5-4D] excluding GC B-cell 
origin. 2/10 (20%) MAD tumors expressed CD5, a marker that is frequently associated with 






expressed by human MCL [Table 5.1, Fig. 5-4D] In addition to DLBCL observed in 2/10 (20%) 
MAD mice, including one exhibiting prominent red pulp involvement, a spectrum of indolent 
lymphoproliferations were noted in the remainder. All 8 lymphoproliferative disorders (LPDs) 
were characterized by variable degrees of white pulp enlargement, predominantly due to 
follicular mantle and marginal zone expansion without discernable GCs. Of note, 5/10 (50%) 
MAD tumors showed significant infiltration of the red pulp by small to medium-sized 
lymphocytes, resembling the pattern of splenic involvement by human CLL and MCL [Table 5.1, 
Fig. 5-5]. The immunophenotype of the DLBCL indicated a non-GC B-cell origin (BCL6-, IRF4+), 
as did that of the LPDs (PAX5+, BCL6-, IRF4+/- and CD138-). Consistent with these 
observations, while 50% (2/4) of MA lymphomas showed IgH variable region gene mutations, 
only 2/10 (20%) of the MAD lymphomas showed evidence of SHM.  These findings suggest that 
CyclinD1 overexpression synergizes with ATM deficiency to promote predominantly pre-GC B-
cell lymphoproliferations recapitulating some morphological and immune phenotypes of human 
MCL.  
 
MAD tumors share a subset of molecular features with human MCL 
To further characterize the genetic lesions that underlie lymphomagenesis in the MAD 
mice, we performed CGH analyses on 3 MAD, 1 MA and 1 MD tumors with high tumor content 
(>50% by FACS). CGH identified a large number of gross chromosomal gains and losses in all 
tumors [Fig. 5-6A]. Specifically, two MAD tumors (3468 and 4161) display focal deletion 






Figure 5-5: Histopathologic and immunophenotypic analyses of B-cell lymphoproliferations of 
MAD mice 
Representative photomicrographs showing the spectrum of B-cell lymphoproliferations observed. (3468, 
H&E) DLBCL. The white pulp is markedly expanded and the architecture effaced by an infiltrate of large 
pleomorphic lymphocytes. The neoplastic cells express B220 (blue). Scattered small disrupted BCL6+ 
germinal centers are seen and the neoplastic cells are BCL6 negative but they show IRF4 expression, 
findings compatible with a DLBCL of non-GC phenotype. (4271, H&E) LPD with red pulp lymphocytic 
infiltrate. The white pulp is disrupted by expansions of the follicular mantle and marginal zones and a 
diffuse infiltrate of small-sized lymphocytes is present in the red pulp. The neoplastic lymphocytes show 
B220 (blue), PAX5 and IRF4(variable) expression and they lack BCL6 expression. (4161, H&E) DLBCL. 
Clusters of large lymphocytes are seen surrounding the white pulp and also infiltrating the red pulp. The 
neoplastic lymphocytes are B220 (blue) and BCL6 negative, but they express PAX5 and show IRF4 
(variable) expression. (3713, H&E) LPD. The white pulp is variably disrupted by expansions of the 
follicular mantle and marginal zones with limited red pulp infiltration. The neoplastic cells express B220 




tumor 3468 [Fig. 5-6B]. Cdkd2a (ink4a/p16) and Rb1 are also deleted in a subset of the MAD 
and MA lymphomas [Fig. 5-6B]. MLL2, a haplo-insufficient tumor suppressor gene in MCL as 
well as DLBCL, is also partially deleted in all tumors tested [Fig. 5-6B]. Meanwhile, Mdm2, 
Cdk4, and Notch1 are moderately amplified (mostly trisome) in several MAD and MA 
lymphomas [Fig. 5-6B]. These changes are consistent with recurrent genetic alterations that 
have been characterized for human MCL (Jares, Colomer et al. 2007). Meanwhile, the CGH 
analyses also identified focal deletions in Ig (chromosome 4) and Igh (chromosome 12) loci 
indicative of B-cell origin. Fine mapping of the Igh locus showed that the deletions in all 3 MAD 
tumors are restricted to the  V-D-J portion of the Igh locus and does not involve the switch 
region located downstream (centrometric of chr 12) [Fig. 5-6D], consistent with the pre-GC 
origin of the MAD tumors. In contrast, MA tumor 2023 shows heterozygous deletion within 
switch region [Fig. 5-6D]. Together with the positive staining for Bcl6, somatic hypermutation, 
this finding suggests that at least a subset of the MA tumors derived from GC or post-GC cells. 
CGH is not able to detect reciprocal translocations. To test whether reciprocal translocation 
involving IgH locus occurred in any of the tumors, we performed chromosome 12 paint together 
with FISH using a probe that hybridizes to the telomeric end of Igh locus (upstream toward the 
Vh region, 5’ IgH, 207) in two MAD (3468 and 4161) and one MA (2594) tumors, for which high 
quality metaphases are available. The analyses revealed heterozygous deletion, but not 
translocation involving the 5’IgH in MAD tumor 4161 and MA tumor 2594 [Fig. 5-6C]. FISH with 
c-Myc probes exclude IgH-Myc translocation in the tumors and CGH analyses suggested that c-
Myc is not grossly amplified in tested MAD or MA tumors. Finally targeted Sanger sequencing of 











Figure 5-6: Comparative Genomic Hybridization (CGH) and FISH analyses of MA and MAD tumors 
A.) Landscape representation of CGH on MAD tumors-3468 and 4161, with green arrows indicating 
particular regions of interest. Chromosome (Ch.) numbers indicated at the top. The errors indicated the 
loci of interests (i.g. Ig, Igh and Trp53). The y-axis represents the log ratio of copy number between 
tumor vs normal at given probe. B.) Heatmap showing focal deletion of Trp53, Cdkn2a, MLL2 and Rb and 
potential trisomy of Mdm2 and Cdk4. It also shows that normal copy number of c-Myc. Different rows 
represent unique probes used for CGH analyses.  C.) Chromosome (Ch.) 12 paint analyses combined 
with either Telomeric Igh FISH (BAC 207 at the Vh region) or c-Myc on MAD tumors-3468 and 4161. The 
diagram on the right represents the mono-allelic deletion of the Igh in tumor 4161. D.) CGH analysis of 
the Igh locus of MAD, MA, MD tumors. Demarcations of each region within the Igh locus are shown 




of MMSET, two genes that are mutated in ~10% human MCL (Bea, Valdes-Mas et al. 2013). 
Together, these findings suggest that MAD tumors share molecular features with human MCL. 
 
ATM deficiency enhances genomic instability and increases chromosomal fusions in 
CyclinD1+ B cells. 
 To better understand the mechanism by which ectopic CyclinD1 expression synergizes 
with ATM deficiency to promote B-cell lymphoproliferations, we analyzed non-neoplastic B-cells 
from 6-12 week old MAD and MA mice. MCL is thought to originate from pre-GC, mantle zone 
B-cells that have yet to encounter CSR and SHM (Walsh, Thorselius et al. 2003). As ATM 
deficiency reduces CSR efficiency (Lumsden, McCarty et al. 2004, Reina-San-Martin, Chen et 
al. 2004), we hypothesized that ectopic expression of CyclinD1 and ATM deficiency together 
might be deleterious to cells undergoing CSR, thus effectively trapping naïve B-cells at the pre-
GC stage of development/maturation. To test this hypothesis, we measured CSR in purified B-
cells derived from MA and MAD mice as well as WT or Atm-/- control mice in vitro. Ectopic 
expression of CyclinD1 by itself did not measurably affect CSR. In vitro CSR to IgG1, measured 





Figure 5-7: Cell Cycle Analyses of stimulated B-cells from MA, MAD and MD/D mice. 
LPS/IL4 activated B-cells (Day 3) were pulsed in BrdU for 30 min without IR or 12 or 24hr after IR. The 
percentage of BrdU positive cells were plotted in A.) and the ratio of BrdU+ cells post-IR/before IR were 
quantified below. The percentage of mitotic cells (indicated by phosphorylated Ser10 of Histone H3 (pH3) 
was quantified before and 2 or 12 hr after IR (10Gy) in B.). 
 
B-cells [Fig. 5-8A], suggesting ATM deficiency compromised CSR in WT and CyclinD1+ B cells 




activated B-cells are normal in WT and CyclinD1+ B-cells and comparable in Atm-/-, MA and 
MAD B cells  [Fig. 5-7A, 5-7B], suggesting that ATM deficiency compromised DNA damage 
induced checkpoints in both WT and CyclinD1+ B-cells [Fig. 5-7A, B]. Next, we assessed the 
degree of genomic instability in LPS/IL4 activated B-cells from Atm-/-, MA and MAD mice by 
Telomere-FISH (T-FISH) analyses. Two kinds of breaks can be quantified by the T-FISH assay: 
chromosomal breaks, which refer to breaks at both sister-chromatids, and chromatid breaks, 
which refer to breaks in only one of the two sister-chromatids [Fig. 5-8B] The frequencies of 
chromosomal breaks as well as chromatid breaks were comparable in MA and MAD mice and 
significantly higher than those observed in MD mice [Fig. 5-8B]. Moreover, the frequency of 
dicentric chromosomes generated by end-end fusion of chromosomal breaks was significantly 
higher in activated B-cells derived from MAD mice than in those from the MA or MD mice [Fig. 
5-8C] suggesting possible increased proclivity of chromosomal translocations. We conclude that 
ATM deficiency induces genomic instability in CyclinD1+ B cells. 
 
Ectopic CyclinD1 expression increases naïve B-cell proliferation and rescues the B-cell 
lymphocytopenia in older MA mice. 
Given the majority of the MAD and MA lymphomas are IgM+ and thus derived from cells 
that have not yet undergone CSR, we compared the naïve B-cell population in young (1-3 
month old) vs mid-age (4-6 and 7-12 month old) MAD and MA mice. While all mature B-cell 
population are present in 6 and 12-month old MAD, MA and MD/D controls, the frequency of 
naïve B-cells (CD19+ cells) in spleen declined significantly faster in MA mice, recapitulating the 
ATM deficient B-cell lymphocytopenia that worsens over time [Fig. 5-9A, B].  Ectopic expression 
of CylinD1 alone has, at most, moderate effects on splenic B-cell frequency in WT mice (MD vs 





Figure 5-8: Increased chromosomal fusions in stimulated MAD B-cells 
A.) Representative flow cytometry plots for surface IgG1 expression in LPS/IL4 stimulated B-cells and 
quantification. Efficiency is calculated as a percentage of IgG1+ cells relative to the control. B.) 
Representative images of cytogenetic abnormalities observed in T-FISH assay in stimulated splenic B-
cells and the quantification. C.) Quantification of dicentric chromosomes observed stimulated B-cells 
derived from MD/D, MA, MAD, and Atm
-/-
 mice. P-values were calculated using a two-tailed Student’s t-
test assuming unequal variances. 
 
[Fig. 5-9A, B]. This is intriguing, since the naïve B-cell population is thought to be the progenitor 
of MCL lymphomas. We then co-stained splenic sections from 6 month old tumor-free mice with 
B-cell marker-B220 and proliferation marker-Ki67. Quantification of Ki67+B220+ cells revealed a 
significant reduction of Ki67+ frequency in B-cells from MA mice, which is rescued by ectopic 





Figure 5-9: CyclinD1 expression rescues progressive B-cell loss in MA mice 
A.) Representative flow cytometry plots of splenic B220+CD19+/IgM+ B-cell populations in 6-month old 
mice. B.) Quantification of CD19+ B-cell populations from non tumor-bearing mice analyzed at the 
indicated time points. C.) Representative immunofluorescence (IF) images, and D.) Quantification of 
Ki67+ (green, nuclear staining) and B220+ (red, membrane staining) cells in spleens harvested from 7-
month old non-tumor mice. Fields [MD (n=7), MA (n=15), and MAD (n=14)] selected for quantification 
were taken at 400x total magnification with equivalent B220+ cellularity. P-values were calculated based 





ectopic expression of CyclinD1 promotes proliferation of ATM-deficient naïve B-cells with 
genomic instability, rescue the B-cell lymphocytopenia, and promote lymphomagenesis in pre-




Given the mature B-cell phenotypes of most ATM–deficient human B-cell lymphomas and 
the well-characterized role of ATM during CSR, it was speculated that ATM maintains genomic 
stability in GC-B cells to suppress B cell lymphomas. However, despite complete ATM deletion 
in naïve B cells, our attempt to establish an ATM-deficient mature B-cell lymphoma model with 
naïve B-cell specific CD21Cre or less robust pre-B-cell specific CD19-Cre was fruitless. Mb1Cre 
allele is an early and robust B-cell specific Cre that leads to Cre activation in almost all pre-B-
cells (in contrast to ~60% of pre-B-cells via CD19Cre). In this regard, 16.7% of MA and ~55% of 
MAD mice developed indolent yet clonal, mature B-cell lymphomas [Fig. 5-4B] recapitulating the 
disease spectrum of human lymphomas, especially MCL. Even so, most of the MA and MAD 
tumors are IgM+ and thus have not undergone CSR. Fine mapping of the Igh loci with CGH 
probe and FISH analyses further revealed V(D)J recombination-related, but not CSR-related 
chromosomal alterations in MAD tumors. Together these findings highlights the critical tumor 
suppressor function of ATM in early progenitor or naïve B cells, possibly during V(D)J 
recombination,  to prevent mature B cell lymphomas down the line. In this context, ATM is 
known to prevent the persistence and propagation of chromosome breaks originating from 
V(D)J recombination in naïve B-cells(Callen, Jankovic et al. 2007). Recent studies reveal that 
early genetic alterations in hematopoietic stem cells could prime mature B-cell malignancies, 




Despite strong evidence for a role of CyclinD1 lymphomagenesis, mice with ectopic 
expression of WT CyclinD1 (MD/D) rarely developed lymphomas. Genomic analyses of human 
MCL suggest that ATM deletion coexist with CyclinD1 expression in nearly 50% of MCLs (Bea, 
Valdes-Mas et al. 2013). Here we show that ATM deletion promotes B-cell lymphomagenesis in 
EµCyclinD1 mice (Bodrug, Warner et al. 1994, Vaites, Lian et al. 2014). While ATM deficiency 
and the resulting genomic instability might simply promote IgH-CyclinD1 translocation in human 
MCL, our study suggests that loss of ATM also promotes lymphomagenesis after ectopic 
expression of CyclinD1. In this context, we showed that ATM deficiency increases genomic 
instability and chromosomal translocations in activated CyclinD1+ B-cells [Fig. 5-8A]. This 
increased genomic instability in naïve B cells likely promotes the loss of additional tumor 
suppressor genes including Trp53, Cdkn2a, MLL2 or Rb1 that have all been implicated in 
human MCL to promote transformation(Bea, Valdes-Mas et al. 2013).  In addition, ATM 
deficiency might potentiate the mitogenic function of CyclinD1 by increasing CyclinD1 protein 
levels. ATM negatively regulates F-Box proteins (FBX4 and FXBO31) that mediate the 
degradation of CyclinD1 during DNA damage responses (Santra, Wajapeyee et al. 2009, 
Vaites, Lee et al. 2011). Indeed, germ line ATM deficiency accelerates lymphomas in mouse 
models expressing a constitutive-nuclear form of CyclinD1 (Gladden, Woolery et al. 2006, 
Vaites, Lian et al. 2013).   
MAD mice developed B-cell lymphomas significantly earlier and more frequently than 
MA mice, suggesting that mitogenic cues generated by ectopic CyclinD1 expression synergize 
with ATM deficiency for B-cell transformation. In addition to its checkpoint function, ATM has 
important roles in DNA repair, as ATM deficiency is detrimental to primary cells due to ongoing 
genomic instability. Here we show that B-cell-specific deletion of ATM in MA mice leads to 
progressive B-cell lymphocytopenia at 6- and 12- months of age [Fig. 5-9A, B], a phenotype that 




that EµCyclinD1 promotes the proliferation of naïve B-cells and successfully restores B-cell 
cellularity in older MA mice [Fig. 5-9A-D]. Based on this finding, we propose that CyclinD1 
promotes B cell lymphomas by promoting proliferation of ATM naïve B cells with genomic 
instability, which in turn maintain the cellularity of tumor-prone ATM-deficient B-cells. There are 
three D-type cyclins (D1, D2 and D3) with overlapping functions during embryonic development 
(Carthon, Neumann et al. 2005, Ciemerych and Sicinski 2005), but GC B-cells exclusively 
depend on CyclinD3 for proliferation and survival (Peled, Yu et al. 2010, Cato, Chintalapati et al. 
2011), which might explain why the pre-GC cells are more susceptible to the mitogenic cues 
unleashed by ectopic CyclinD1.  
In summary, we report the first animal model for ATM-deficient B-cell lymphomas and 
reveal a synergistic role of CyclinD1 expression and ATM deficiency in naïve B-cells to promote 
pre-GC B-cell lymphomas. The MA and MAD mature B-cell lymphomas are largely indolent, 
similar to the Bcl6-driven mouse lymphomas (Cattoretti, Pasqualucci et al. 2005) and distinct 
from Myc driven aggressive lymphomas. In this regard, MA and MAD lymphomas recapitulate 
the disease spectrum of human lymphomas, especially MCL (Zullo, Amengual et al. 2012), and 
would be an invaluable resource to better understand MCL and the clinical progression of 









IMPLICATIONS, FUTURE DIRECTIONS 
 
 
Novel kinase-structure roles of ATM in DNA repair, lymphomagenesis  
 
Much of the understanding of ATM function to date has been on its signaling function, 
while its structural functions, if any, remained elusive. To address this, we generated mice 
expressing a kinase-dead ATM protein initially to test whether catalytically inactive ATM would 
rescue any of the pleiotropic phenotypes associated with complete loss of ATM in DNA repair 
and lymphomagenesis. Strikingly, while ATM-null mice are viable, mice solely expressing KD 
ATM are embryonic lethal with severe genomic instability beyond that seen in ATM null mice, 
suggesting the presence of the catalytically inactive ATM inhibits additional DNA repair 
pathways. In this context, we found that the catalytically inactive ATM protein, but not the lack of 
ATM, suppresses the replication dependent strand cleavage necessary for Top1cc removal, 
which manifests to increased chromatid breaks, accumulation of Top1cc and hypersensitivity to 
CPT as well as inhibitors for PARP that is implicated in the repair of Top1cc lesions. Strikingly, 
expressing ATM KD is more oncogenic than loss of ATM in mouse lymphoma models, at least 
in part due to frequent deletion of the Pten tumor suppressor gene in the progenitors. Based on 
these findings, we propose that ATMKD/- cells and, by extension ATMKD/- lymphomas, might be 
preferentially targeted by Topo1 inhibitors. The generation and characterization of the mouse 
model expressing catalytically inactivate ATM described here for the first time, revealed a 
phosphorylation-dependent structural function of ATM upstream of DSBs that have several 
implications in ATM function beyond its roles in DDR, and tumor suppression.  
Several studies have identified several functions of ATM outside its role in classical DNA 
DSB repair, including ROS processing, insulin signaling, hypotonic stress response, cell 
migration and metastasis, and cellular metabolism (Yang and Kastan 2000, Eaton, Lin et al. 




al. 2015). While Cys2991 of ATM has been implicated in its ROS response (Guo, Kozlov et al. 
2010), it is largely unknown whether these “non-canonical” functions of ATM only require its 
kinase activity, whether the AtmKD/- cells retains (or loses) these functions. AtmKD/- cells and 
mice described here provide a platform to answer these questions, and will contribute to further 
understanding the ever-expanding roles of ATM beyond the DNA damage response. ATM-null 
thymocytes accumulate ROS at greater levels compared to WT thymocytes and antioxidants 
delay the onset of thymic lymphomas in Atm-null mice via treatment with (Schubert, Erker et al. 
2004, Valentin-Vega, Maclean et al. 2012, D'Souza, Parish et al. 2013). The effect of ATM KD 
in ROS processing or other non-canonical function of ATM are yet to be determined, and might 
contribute to the increased oncogenic potential associated with Atm KD mutation.  
Given the prevalence of ATM missense mutations in human cancer and the 
hypersensitivity of AtmKD/- cells to CPT, these results suggest that we might be able to target 
ATM with Topo1 inhibitors- a class of drugs that is already used in cancer therapy. In this 
precision medicine era, the identification of ATM mutations in tumors can serve as a marker to 
tailor therapeutic regimens to include Topo1 inhibitors in treatment. We are currently testing this 
using a murine models of activated Notch-driven AtmKD/-, AtmC/+ vs Atm-/- T cell leukemia 
models. Specifically, we had induced immature T cell leukemia by infecting  bone marrows from 
Rosa+/ERCRE AtmC/+, AtmC/C, or AtmC/KD mice with retrovirus encoding the oncogenic form of 
Notch1 (ΔE-NOTCH1)(Pear, Aster et al. 1996, Schroeter, Kisslinger et al. 1998). We then 
transplanted the established leukemia to secondary recipients and induced Cre activation via 
Tamoxifen to generate isogenic Atm+/-, Atm-/- and Atm-/KD leukemias, respectively. Once the 
deletion is confirmed and the clonality of leukemia is established, we will perform tertiary 
transplantation to new recipients with isogenic AtmC/KD vs Atm-/KD or Atm+/c vs Atm+/- leukemias 
and subject the recipient mice to Irinotecan- a clinically used Topoisomerase-I inhibitor. The 
results from these ongoing experiments will provide important preclinical data to determine 




Furthermore, these ongoing experiments will uncover potential complications and information, 
including dosage, side effects, and in vivo efficacy of the therapy.   
 
 
Mutational landscape of ATM in human tumors- prognostic and therapeutic significance  
 
 The increased oncognic potential of AtmKD/- allele and the prevalence of kinase domain 
missense mutation in human cancers we found here revealed a feature of highly oncogenic 
ATM mutations – defined by the expression of KD ATM, and a potential indicator for Topo1 
inhibitor-based therapy. But the requirement for MRE11 protein, but not its nuclease activity in 
how ATM KD protein suppress CPT induced DSBs, also suggest the potential genetic modifiers 
that might alter the phenotype of ATM KD alleles. We recently identified a hotspot mutation at 
Arg3008 to R3008H or R3008C in the FATC domain. Structural analyses put the R3008 on the 
surface of ATM and at the end of an alpha helix that is likely important for helix stability [Fig. 1-
1]. Preliminary characterization of the mice generated with knock-in Atm R3008H (R3018H in 
mice, R allele) mutation confirmed that AtmR/R MEFs express near wildtype levels of ATM 
protein, but fail to phosphorylate KAP1 upon IR treatment, as indicated in previous studies on 
human lymphomas with R3008 mutations [Fig. 3-1C, 0-1] (Camacho, Hernandez et al. 2002, 
Angele, Lauge et al. 2003, Austen, Barone et al. 2008). While Atm+/R mice, like the Atm+/KD mice, 
do not display any discernable dominant-negative phenotypes (Yamamoto, Wang et al. 2012), 
both AtmR/R and AtmR/- mice are small (~50%), yet born alive, in contrast to the early embryonic 
lethality of AtmKD/KD(KD/-) mice (Yamamoto, Wang et al. 2012). Given the R3008 residue is 
located outside of the catalytic core of ATM [Fig. 1-1, Fig. 4-6C, residue labeled in red], one 
possibility is that ATM R3008H is still a viable kinase, but the ATM R3008H cannot be activated 
by DSBs since the R3008H mutation abrogates its ability to interact with MRE11-NBS-RAD50 





Figure 0-1: ATM R3008H (R) retains protein expression and lacks kinase activity 
Western blot of immortalized MEFs with the indicated genotypes with or without IR. Experiment testing 




 MEF lines are shown.  
 
yeast, is required for ATM recruitment to the damage site and for its activation by DNA damage 
(Ogi, Goto et al. 2015). While additional work is necessary to further elucidate the consequence 
of the R3008H mutation in DNA repair, tumorigenesis, and treatment responses both in vitro 
and in vivo, these preliminary results further extend the complexity associated with ATM 
mutations and emphasize the importance of developing a functional-based system to classify 
cancer associated ATM mutations.   
 
Functions of ATM in the suppression of B-cell lymphomas 
 
 Both germline and somatic mutation of ATM were found in human B cell lymphomas, yet 
several previous efforts of generating ATM deficient B cell lymphomas models have been 
fruitless. While Atm deletion using CD19-cre, which begins to express at the Pre-B stage, did 
not result in the development of B-cell lymphomas, deletion of Atm using Mb1cre, expressed at 
the early Pro-B cell stage, resulted in the development of clonal, mature B-cell lymphomas in 
~50% of the mice, providing a functional validation for the need of early deletion of ATM during 




indolent forms of lymphomas seen in the clinic, thus serves as a suitable model to study early 
stage B-cell lymphomas. The synergistic effect of ATM deletion and CyclinD1 overexpression in 
driving pre-GC mature B-cell lymphomas, which share histopathological features with human 
MCL, further provides a faithful animal model for MCL- a disease for which effective therapy is 
not yet available (Herrmann, Hoster et al. 2009). We further showed that this synergy is 
associated with increasing genomic instability and expansion of the proliferative naïve B-cell 
pool in the spleen, providing a mechanism for how ATM loss and CyclinD1 work together in 
MCL. Missense mutation in the kinase domain of ATM is also found in MCL, [Fig. 4-5A] 
(Stankovic, Stewart et al. 2002) suggesting that ATM KD may increase the overall incidence 
and accelerate the kinetics of B-cell lymphomas compared to the loss of ATM. Furthermore, 
ATM KD-bearing B-cell lymphomas can potentially be targeted by Topo1 inhibitors for therapy. 
We are currently developing a mouse model utilizing the Mb1cre to conditionally express ATM 
KD in B-cells. If the ATM KD leads to earlier and increased development of B-cell lymphomas, 
this will provide further insight into the nature of the ATM KD mutation in promoting 
lymphomagenesis in the context of B-cells. Additionally, the mice generated in this study will 
serve as an invaluable resource to identify novel therapeutic interventions tailored for ATM 










Generation of ATM KD, DKDtg allele 
The DNA sequence for homologous targeting at the Atm locus was generated via PCR 
from TC1 ES cell DNA (129 strain). A targeting construct was designed to insert a NeoR gene 
cassette oriented in the opposite transcriptional direction from the endogenous Atm promoter 
into intron 57 next to the D2880A/N2885K mutation in exon 58. A 3.5 kp 5’ arm and 5.1 kb 3’arm 
were PCR generated separately, cloned into pBK vector and sequenced. The 5’arm was directly 
subcloned into pLNTK in the desired orientation. The mutation was introduced into the 3’ arm 
using site-direct mutagenesis and confirmed by sequencing. The mutated 3’ was then sub-
cloned into pLNTK. The targeting construct was then electroporated into CSL3 ES cells (129 
strain) and successful targeting was determined via Southern blot analyses using EcoRV 
digested genomic DNA and 5’ genomic probe as outlined in [Fig.2-1B]. The WT band is ~22kb 
and the targeting introduced an additional EcoRV site and reduced the band to ~4.7kb. The 
corrected clones were confirmed with 3’ probe with EcoRV digestions. Six independent targeted 
clones were sequenced for the ATM KD mutation, 4 were verified with correct mutations. Two 
were injected for germ line transmission.  
The DKD allele was generated by introducing S1987D and D2880A/N2885K mutations 
into BAC RP24-122F10, which contains Atm and genomic regions 18kb downstream and 50kb 
upstream of the stop and start codons, respectively, using a “hit and fix” BAC recombineering 
technique previously described (Yang and Sharan 2003). Linearized BAC containing the 
mutations were injected into the pronuclei of fertilized embryos and into a surrogate. Chimers 








 AtmC/C and Rosa+/ER-Cre mice were previously characterized (de Luca, Kowalski et al. 
2005, Guo, McMinn et al. 2007, Zha, Sekiguchi et al. 2008, Zha, Jiang et al. 2011). To activate 
Cre-recombination, Rosa+/ER-Cre mice were orally fed with Tamoxifen (5 mg/100µl with 10% 
ethanol in Sunflower oil per mouse) daily for two consecutive days. The mice were analyzed 10-
14 days after the 2nd treatment. All animal experiments were conducted in pathogen free facility 
and approved by the Institute Animal Care and Use Committee of Columbia University.  
 
Derivation of Embryonic Stem Cells from Mice 
 3-4 week old female Atm+/KDN mice were super-ovulated by intraperitoneal injection of 
5.0 IU pregnant mare serum gonadotropin (PMS), followed by intraperitoneal injection of 5.0 IU 
hCG (Sigma) 46 to 48 hours later. The females were set up with adult male Atm C/C mice (1:1 
ratio) immediately after the hCG injection. Four days after the hCG injection, the mated females 
were sacrificed and mature blastocysts were flushed out of the uterus and plated one per well in 
96 well plates containing irradiated feeders. After 9-14 days incubation, the cells were expanded 
to 24 well plates, at which stage, half of the cells were frozen down and the rest of the cells 
were used to derive DNA for genotyping. Atm KDN/C ES cells were then identified by PCR. 
 
Cytogenetic analysis for genomic instability 
 ES cells, not grown on feeders, were plated 24 hrs before the addition of colcemid 
(KaryoMAX Colcemid Solution, GIBCO) at 100 ng/ml for 1-2 hours.  ES cells were harvested by 




described (32). Briefly, telomeres were stained with a Cy3-labled (CCCTAA)3 peptide nucleic 
acid probe (PNA, Biosynthesis Inc.) and DNA was counter-stained with DAPI-containing 
mounting media (Vectashield®).  Images were acquired using Nikon Eclipse 80i with remote 
focus accessory and with Photometrics® CoolSNAP™ HQ2 camera unit with the Plan Fluor 
Nikon Lens (60x and 100x/1.30 Oil, Japan) in room temperature. All images were processed 
with NIS-Elements AR (Ver. 3.10). Chromosome breaks were defined by loss of telomere signal 
from both sister-chromatids. Chromatid breaks were defined by loss of telomere signal from one 
of the two sister-chromatids or a clearly broken DAPI signal in the middle of one chromatid. We 
note that chromosomal gaps could not be reliably identified with the T-FISH assay; therefore, it 
is possible that the actual frequency of chromatid or chromosome breaks might be even higher 
than estimated.   
 
Lymphocyte Development and Class Switch Recombination 
 Lymphocyte populations were analyzed by flow cytometry as described (Li, Alt et al. 
2008). Isolation and activation of splenic B cells and flow cytometric assays were performed as 
described (Li, Alt et al. 2008). Briefly, CD43- splenic B cells were purified from total spleen using 
anti-mouse CD42 MACS bead following the manufacturer’s instructions (Miltenyi). To stimulate 
the cells for CSR, the cells were incubated with αCD40 plus IL-4 for 4 days and the percentage 
of CSR to IgG1 were determined by surface staining and FACS analysis (Li, Alt et al. 2008). To 
assay for genomic instability, Colcemid was added to a fraction of day4 stimulated B cells for 4 








CHAPTER 3  
 
Mouse Embryonic Fibroblasts (MEF) 
 MEFs were harvested at embryonic day 14.5 (E14.5) based on timed breeding and 
immortalized using retrovirus expression the large and small SV40 T antigen. Immortalized 
culture was established after three passages (1:3 dilutions) after the primary infection. To 
induce 4-hydroxytamoxifen (4OHT) dependent nuclear translocation of ER-Cre recombination 
[Fig. 3-1] the cells were plated at low density (~30% confluence), passed three times (48h 
interval) in the presence of 4OHT (200nM). Complete deletion of the conditional allele was 
confirmed using PCR as described previously (Yamamoto, Wang et al. 2012). For drug 
sensitivity assays, the immortalized MEF treated for 4OHT (3 rounds) were seeded in 
gelatinized 96-well plates (6x103/well). Twenty-four hours after the initial seeding, the cells were 
treated with the compounds at indicated concentration for 48 hours. The cell number was 
quantified using CyQuant (Molecular Probes), a nucleotide staining, per the manufacturer’s 
instructions. The relative survival was calculated based on the cell number in the untreated 
wells. 
 
Immunofluorescence and quantification of repair protein foci 
 Immunofluorescence was performed on 4% formaldehyde/PBS fixed, 1% Triton-X/PBS 
treated cells using the following antibodies: Rad51 (Clone PC130, 1:200, Calbiochem) phospho-
RPA pT21 (Cat. # ab109394, 1:500, Cell Signaling) γH2AX (Cat. #07-164, 1:500, EMD 
Millipore), CyclinA2 (Clone CY-A1, Sigma-Aldrich). Slides were scanned on the Carl Zeiss Axio 
Imager Z2 equipped with a CoolCube1 camera (Carl Zeiss, Thornwood, NY, USA). Metafer 4 
software (MetaSystems, Newton, MA, USA) was used for automated quantification of Rad51, 
pRPA, γH2AX foci. More than 500 cells were quantified for every experimental replicate. Images 





Western and Southern Blotting 
 Following antibodies were used for Western blot on whole cell lysate: ATM (clone MAT3, 
1:5000), β-Actin (clone A5316, 1:20,000) and Vinculin (clone V284, 1:10,000) from Sigma-
Aldrich; phospho-Kap1 (Cat. #A300-767A, 1:1000) and Top-I (Cat. # A302-590, 1:1000) from 
Bethyl laboratory; phospho-RPA pT21 (Cat. # ab109394, 1:5000) from Abcam; RPA (clone 
RPA30, 1:5000), γH2AX (Cat. #07-164, 1:1000) and H2AX (Cat. #07-627) from EMD Millipore; 
phospho-Chk1 (clone 133D3, 1:500), Mre11 (Cat. #4895S, 1:1000), Kap1/TIF1β (clone 
C42G12, 1:1000), and Pten (clone D4.3 XP, 1:1000) from Cell Signaling and PCNA (clone 
PC10) from Santa Cruz. To confirm deletion of the ATM conditional allele in VKD and VN 
mouse models, Southern blot was performed on KpnI digested genomic DNA and probed with 
using the ATMCKO 3’ probe(Zha, Sekiguchi et al. 2008). For clonal analyses of the thymic 
lymphomas or the B cell lymphomas, Southern blot was performed on EcoRI-digested genomic 
DNA, and blotted with Jβ1.6 Jβ2.7 probes (Khor and Sleckman 2005, Zha, Sekiguchi et al. 
2008) or Jh4 probes or myc-A probe (Gostissa, Yan et al. 2009). 
 
Sister Chromatid Exchange Assay 
Cells were incubated for two doubling times (48hrs) with Bromodeoxyuridine (BrdU, Sigma-
Aldrich, 5µg/ml). During the second doubling period (the 2nd 24hr), the cells were also incubated 
with either vehicle (DMSO) or CPT (1µM) BrdU-incorporated sister chromatids were quenched 
using Hoechst33258 (50µg/ml) treatment followed by UV exposure, then stained with DAPI 
(Vectashield). Slides were scanned for metaphase spreads using the Carl Zeiss Axio Imager Z2 
equipped with a CoolCube1 camera (Carl Zeiss, Thornwood, NY, USA) and Metafer 4 software 




software (MetaSystems). Over 40 metaphases were quantified for each genotype. A total of 
three independent replicates were performed. 
 
COMET Assay 
 Neutral and alkaline COMET assays were performed per manufacturer’s protocol 
(Trevigen). Slides were scanned for COMETs using Metafer 4 and tail lengths quantified using 
ISIS. 
 
In-vitro Complex of Enzymes (ICE) assay 
 Covalent complexes of TopI-DNA were detected as previously described (Nitiss 2001).  
Briefly, cells were gently lysed in 1% Sarkosyl/TE solution, ultracentrifuged through a CsCl2 
gradient (6M) and the resulting genomic DNA was dissolved in TE. Equivalent amounts of DNA 
were loaded on 0.45µm Nitrocellulose membranes, and probed for Top-1 (Cat. # A302-590, 
1:1000, Bethyl). Loading controls were probed with radiolabeled total mouse genomic DNA.  
 
DNA fiber assay 
 Cells were first incubated with 25µM IdU (30 min) then with additional 250µM CldU 
(Sigma), trypsinized and harvested in ice-cold 1xPBS, lysed using 1% SDS/Tris-EDTA and 
stretched along glass coverslips. Slides were stained using primary Anti-IdU (B44, BD 
Biosciences), CldU (BU1/75 (ICR1), Abcam) antibodies and corresponding secondary anti-Rat 
Alexa594, and anti-mouse Alexa488 (Molecular Probes) antibodies. DNA fibers were analyzed 
on the Nikon Eclipse 80i microscope equipped with remote focus accessory and CoolSNAP HQ 




quantified with NIS-Elements AR. Length of fibers were calculated with a base pair length of 




Large Cohort Patient Collection 
 ATM somatic mutations were collected from 5,402 cancer patients from 24 tumor types 
of TCGA, including ACC, BRCA, CHOL, COADREAD, ESCA, HNSC, KIRC, LAML, LIHC, 
MESO, PAAD, PRAD, SARC, STAD, THYM, UCS, BLCA, CESC, COAD, DLBC, GBM, KICH, 
KIRP, LGG, LUAD, OV, PCPG, READ, SKCM, TGCT, UCEC, and UVM. All maf files of those 
tumor types were downloaded using firehose (http://gdac.broadinstitute.org). To unify the 
annotation format, we firstly used liftover tool (https://genome.ucsc.edu/cgi-bin/hgLiftOver) to 
map all coordinates to hg19, and then re-annotated variant effect with VEP 
(http://www.ensembl.org/info/docs/tools/vep/) under transcript NM_000051.3. Mutation types 
Missense_Mutation, In_Frame_Del, and In_Frame_Ins were classified as missense, while 
Nonsense_Mutation, Frame_Shift_Del, Frame_Shift_Ins, and Splice_Site were classified as 
truncating mutations.  
Germline ATM mutations are from A-T patients in the Leiden open variable database LOVD2 
(http://chromium.lovd.nl/LOVD2/home.php?select_db=ATM). Protein mutation position was 
curated annotated based on the mutation effect provide by LOVD2. Start_Codon, 
Frame_Shift_Del, Large_DEL, Nonsense_Mutation, Frame_Shift_Ins, Splice_Site, and 
Stop_Codon are labeled as Truncating in our analysis. 
 
Mutation Density Estimation 
 To measure the mutation density of different ATM positions, we applied a Gaussian 




1,2,⋯ , 𝑛) to represents the number of mutations in each site 𝑥𝑖, then the Gaussian kernel 
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) is the Gaussian kernel, and 𝑏 indicates the window size (we 
use 80 in the current study). Missense mutations and truncating mutations were separately 
considered.  
To estimate the expected number of mutations in ATM, we assume the ratio between silent and 
non-silent mutation (e.g. missense mutation) is constant, and then the frequency, as well as its 
confident interval, to observe a missense mutation can be estimated by fitting a binomial 
distribution with 𝑛 trials. The shadow curve was the 95% confidence interval of fold change 
between observation and expectation after a Bonferroni Correction.  
 
Structure Simulation Analyses 
 Homology model of human ATM was generated based on the crystal structure of human 
mTOR(PDB 4JSP)(Yang, Rudge et al. 2013) using the ROBETTA server, setting default 
parameters(Kim, Chivian et al. 2004). Briefly, the amino acids 2520-3056 of human ATM was 
submitted to the ROBETTA server and the mTOR crystal structure was identified as template. 
After align the query sequence with the parent structure, a template was generated and the 
variable regions were modelled in the context of the fixed template using Rosetta fragment 
assembly.  Finally, the model was subjected to several rounds of optimization by Rosetta’s relax 





Mice and lymphocyte analyses 
 All the mouse alleles used (AtmC, AtmKD, VavCre+, RosaERCre) have been previously 
described (de Boer, Williams et al. 2003, de Luca, Kowalski et al. 2005, Zha, Sekiguchi et al. 
2008, Yamamoto, Wang et al. 2012),. All the animal work were approved by and performed 
according to the regulation of Institutional Animal Care and Use Committee (IACUC) of 
Columbia University. For development analyses, VN, VKD and littermate matched control mice 
were euthanized at 4-6 weeks of age. Total lymphocyte counts, flow cytometry analyses and in 
vitro class switch recombination were performed as described previously (Li, Alt et al. 2008). 
Briefly, splenic B and T-cells were isolated using Magnetic-Activated Cell Sorting (MACS) for 
CD43- and CD43+ fractions, respectively, following the manufacturer’s protocol (Miltenyi Biotec). 
B-cells (CD43-) were stimulated with LPS (20µg/ml) and IL-4 (20ng/ml) for 4.5 days at a cellular 
concentration no more than 1x106cells/ml, and the T-cells (CD43+) activated by ConA (2µg/ml) 
for 3.5 days (Li, Alt et al. 2008). Metaphases were collected at the end of the cytokine 
stimulation period after 4 hours of colcemid (100ng/ml KaryoMax, Gibco) treatment, stained with 
Telomere FISH probes as previously described (Franco, Gostissa et al. 2006, Yamamoto, Wang 
et al. 2012). Lymphoma- bearing animals were identified based on enlarged lymph nodes (B cell 





ATMC/C (Zha, Sekiguchi et al. 2008), EµCyclinD1 transgenic (Bodrug, Warner et al. 
1994), CD21Cre (Kraus, Alimzhanov et al. 2004), CD19Cre (Rickert, Rajewsky et al. 1995) and 
Mb1Cre (Hobeika, Thiemann et al. 2006) mice were previously described. All experimental 




heterozygosity. All animal experiments were performed in accordance with Columbia University 
Institutional Animal Care and Use Committee. 
 
Flow cytometry and Immunohistochemistry analyses  
Flow cytometry analyses were performed on single-cells suspensions from spleen, bone 
marrow, lymph nodes as previously described (Yamamoto, Wang et al. 2012). Antibodies 
include: CD43(S7), CD5(53-7.3), CD138(281.2), CD21/35(7G6), CD23(B3B4), CD11b/Mac-
1(M1/70) and IgK from BD Pharmingen (San Diego, CA); B220(RA3-6B2), CD19(eBio1D3), 
CD8a(53-6.7), CD4(L3T4), CD3ε(145-2C11) and TCRβ(H57-597) from eBioscience (San Diego, 
CA); Ter119 and Gr1(RB6-8C3) from BioLegend (San Diego, CA); IgM and IgD from Southern 
Biotech (Birmingham, AL) and PNA from Vector Labs (Burlingame, CA). Immunohistochemistry 
(IHC) staining was performed on formalin fixed, paraffin-embedded tissue sections as described 
previously using the following antibodies: B220, CD3, PAX5, BCL6, IRF4 and CD138 (Klein, Lia 
et al. 2010). Immunofluorescence on paraffin-embedded tissues was performed using 
antibodies against Ki67 (SP6, Abcam, Cambridge, MA), and B220 (RA-3B62, BD Pharmingen). 
Images were acquired with a Nikon Eclipse 80i microscope (Nikon, Melville, NY) and processed 
on NIS-Elements AR 3.10 software (Nikon, Melville, NY).  
 
Southern Blot and Western Blot Analyses 
For Southern blot analyses, genomic DNA from the spleen, tumor and corresponding 
kidneys was digested with EcoRI (for JH4, c-Myc, constant region of TCRδ probe) KpnI (for 3’ 
ATM CKO probe), or HindIII (for the IgK probe) (Zha, Sekiguchi et al. 2008, Gostissa, Yan et al. 
2009, Zha, Bassing et al. 2010). To avoid cross-reactivity with the EµCyclinD1 transgene that 




amplification with the following primers: 5’-TGGTGACAATTTCAGGGTCA-3’ and 5’-
TTGAGACCGAGGCTAGATGC-3’. For Western blots, stimulated splenic B or T-cells were 
probed with antibodies against ATM (1:2000, MAT3, Sigma, St. Louis, MO), pKap1 (1:2000, 
Bethyl, Montgomery, TX), Kap1/TIF1β (1:1000, Cell Signaling, Danvers, MA), β-Actin (1:10,000, 
A5316, Sigma) and CyclinD1 (1:1000, Abcam).  
 
Class Switch Recombination and FISH analyses 
Splenic B-cells from 8-12 week old mice were purified with anti-CD43 MACS beads and 
stimulated with LPS/IL4 for 2-4 days as described previously (Yamamoto, Wang et al. 2012). 
Metaphases were obtained at day 4.5 after stimulation and stained with Cy3 conjugated PNA 
probe against 3xtelomere sequence as previously described (Franco, Gostissa et al. 2006). 
Tumor metaphases were harvested after 6 hours incubation in RPMI1640 with15% Fetal Bovine 
Serum in the presence of colcemid (100ng/ml, KaryoMax, Gibco). Chromosome 12 paint was 
obtained from Applied Spectral Imaging (Carlsbad, CA) and the 5’ c-myc (C10) and 5’ IgH 
(BAC207) locus-specific FISH probes were described previously (Franco, Gostissa et al. 2006). 
Images were acquired with Zeiss Axio Imager Z2 equipped with a CoolCube1 camera (Carl 
Zeiss, Thornwood, NY) and an automatic stage system, and processed with Isis and Metafer4 
software packages (MetaSystems, Newton, MA). 
 
Mutation analyses  
 Somatic hypermutation status of the IgH variable region was determined as described 
(Jolly, Klix et al. 1997). Briefly, degenerative forward primers upstream of J558FR3 (5’-
CAGCCTGAC ATCTGAGGACTCTGC-3’), VH7183 (5’-GAASAMCCTGTWCCTGCAAATGASC-




downstream of JH4 (5’-CTCCACCAGACCTTCTAGACAGC-3’). Rearrangements were defined 
as clonal when a unique band was obtained from a given tumor in three independent PCR 
reactions generated from the same primer pair and characterized/verified by genomic 
sequencing. The results were aligned with normal mouse IgH locus sequences for 129S (NCBI 
accession number: AJ851868.3) and C57BL/6J (NC_000078.6) strains respectively to identify 
somatic mutations in the JH4 intron.  
 Targeted Sanger sequencing of the NOTCH1 (PEST domain) and WHSC1/MMSET 
(SET domain) hotspots were performed on PCR amplified genomic DNA using the following 
primer sets: Notch1:5’- CCAGCCAGTACAACCCACTA-3’ and 5’ 
TTCCAGCTTCCCTTCTCCTG-3’; WHSC1: 5’-GGACCTGAGTTCTGTTCCCA-3’, 5’-
ACACCACAGTCTACAGCGAA-3’; 5’-AGCCCATTGTTCTAGCTGGT-3’, 5’-
GAAGCAATGCAACACCAGGA-3’. Following primers were used to sequence the respective 
product for better depth and coverage:  Notch1: 5’-CCTCCTTCCCAGCACAGTTA-3’, WHSC1: 
5’-AACGCGTTACCCTAGACTGA-3’ and 5’-CTGTCCTCACCAGTGCTCA-3’. Sequences were 
aligned with uc008ivl.2 (NOTCH1) and uc012duw.1 (WHSC1) from the Mouse Genome 
Browser (http://genome.ucsc.edu). 
 
Comparative Genomic Hybridization (CGH)  
 2µg genomic DNA from tumor and non-tumor control (kidney or tail) from the same 
mouse were labeled with Cy-5 and Cy-3, respectively, using the SureTag DNA Labeling Kit 
(Agilent, Santa Clara, CA) per manufacturer’s instructions. Hybridization and scanning was 
performed on a 244k Mouse Genome CGH microarray platform (Agilent) at the Integrated 
Genomics Operation (IGO) Center at the Memorial Sloan Kettering Cancer Center (New York, 
NY). Data analysis was performed on Agilent Genomic Workbench (ver. 7.0.4.0) and Microsoft 
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